<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK476672" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK476672/" /><meta name="ncbi_pagename" content="Hyperphosphatemic Familial Tumoral Calcinosis - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Hyperphosphatemic Familial Tumoral Calcinosis - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Hyperphosphatemic Familial Tumoral Calcinosis" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/02/01" /><meta name="citation_author" content="Mary Scott Ramnitz" /><meta name="citation_author" content="Rachel I Gafni" /><meta name="citation_author" content="Michael T Collins" /><meta name="citation_pmid" content="29389098" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK476672/" /><meta name="citation_keywords" content="Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome (FTC/HHS)" /><meta name="citation_keywords" content="HFTC" /><meta name="citation_keywords" content="Hyperostosis-Hyperphosphatemia Syndrome" /><meta name="citation_keywords" content="Primary Hyperphosphatemic Tumoral Calcinosis" /><meta name="citation_keywords" content="Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome (FTC/HHS)" /><meta name="citation_keywords" content="HFTC" /><meta name="citation_keywords" content="Hyperostosis-Hyperphosphatemia Syndrome" /><meta name="citation_keywords" content="Primary Hyperphosphatemic Tumoral Calcinosis" /><meta name="citation_keywords" content="Fibroblast growth factor 23" /><meta name="citation_keywords" content="Klotho" /><meta name="citation_keywords" content="Polypeptide N-acetylgalactosaminyltransferase 3" /><meta name="citation_keywords" content="FGF23" /><meta name="citation_keywords" content="GALNT3" /><meta name="citation_keywords" content="KL" /><meta name="citation_keywords" content="Hyperphosphatemic Familial Tumoral Calcinosis" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Hyperphosphatemic Familial Tumoral Calcinosis" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Mary Scott Ramnitz" /><meta name="DC.Contributor" content="Rachel I Gafni" /><meta name="DC.Contributor" content="Michael T Collins" /><meta name="DC.Date" content="2018/02/01" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK476672/" /><meta name="description" content="Hyperphosphatemic familial tumoral calcinosis (HFTC) is characterized by:" /><meta name="og:title" content="Hyperphosphatemic Familial Tumoral Calcinosis" /><meta name="og:type" content="book" /><meta name="og:description" content="Hyperphosphatemic familial tumoral calcinosis (HFTC) is characterized by:" /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK476672/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/hyper-ftc/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK476672/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88A54BDFC759110000000008120408.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK476672_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK476672_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/hhhs/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/hyper-card/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK476672_"><span class="title" itemprop="name">Hyperphosphatemic Familial Tumoral Calcinosis</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome (FTC/HHS), HFTC, Hyperostosis-Hyperphosphatemia Syndrome, Primary Hyperphosphatemic Tumoral Calcinosis</div><p class="contrib-group"><span itemprop="author">Mary Scott Ramnitz</span>, MD, <span itemprop="author">Rachel I Gafni</span>, MD, and <span itemprop="author">Michael T Collins</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK476672_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK476672_ai__"><div class="contrib half_rhythm"><span itemprop="author">Mary Scott Ramnitz</span>, MD<div class="affiliation small">Section on Skeletal Disorders and Mineral Homeostasis<br />Craniofacial Skeletal Diseases Branch<br />National Institute of Dental and Craniofacial Research<br />National Institutes of Health<br />Bethesda, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.rcdin@smztinmar" class="oemail">vog.hin.rcdin@smztinmar</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Rachel I Gafni</span>, MD<div class="affiliation small">Section on Skeletal Disorders and Mineral Homeostasis<br />Craniofacial Skeletal Diseases Branch<br />National Institute of Dental and Craniofacial Research<br />National Institutes of Health<br />Bethesda, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.rcdin@rinfag" class="oemail">vog.hin.rcdin@rinfag</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Michael T Collins</span>, MD<div class="affiliation small">Chief, Section on Skeletal Disorders and Mineral Homeostasis<br />Craniofacial Skeletal Diseases Branch<br />National Institute of Dental and Craniofacial Research<br />National Institutes of Health<br />Bethesda, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.rcdin.rid@snillocm" class="oemail">vog.hin.rcdin.rid@snillocm</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 1, 2018</span>.</p><p><em>Estimated reading time: 30 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="hyper-ftc.Summary" itemprop="description"><h2 id="_hyper-ftc_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Hyperphosphatemic <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> tumoral calcinosis (HFTC) is characterized by:</p><ul><li class="half_rhythm"><div>Ectopic calcifications (tumoral calcinosis) typically found in periarticular soft tissues exposed to repetitive trauma or prolonged pressure (e.g., hips, elbows, and shoulders); and</div></li><li class="half_rhythm"><div>Painful swellings (referred to as hyperostosis) in the areas overlying the diaphyses of the tibiae (and less often the ulna, metacarpal bones, and radius).</div></li></ul><p>The dental <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> unique to HFTC includes enamel hypoplasia, short and bulbous roots, obliteration of pulp chambers and canals, and pulp stones. Less common are large and small vessel calcifications that are often asymptomatic incidental findings on radiologic studies but can also cause peripheral vascular insufficiency (e.g., pain, cold extremities, and decreased peripheral pulses). Less frequently reported findings include testicular microlithiasis and angioid streaks of the retina.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>HFTC results from a relative deficiency of &#x02013; or resistance to &#x02013; the phosphate-regulating hormone, fibroblast growth factor 23 (FGF23). The clinical diagnosis of HFTC is established by the presence of tumoral calcinosis and/or characteristic laboratory findings of hyperphosphatemia in the setting of inappropriately increased renal tubular reabsorption of phosphorus (TRP), elevated or inappropriately normal 1,25-dihydroxyvitamin D<sub>3</sub> (1,25D) levels, and elevated C-terminal FGF23 fragments. Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>FGF23</i>, <i>GALNT3</i>, or <i>KL</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> confirms the diagnosis when clinical and laboratory findings are inconclusive.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> No randomized clinical trials have been performed; studies of the treatment of HFTC consist of case reports or case series. Since FGF23 replacement therapy is not available, treatment relies on lowering blood phosphorus by blocking absorption from the diet (i.e., use of low-phosphate diet and phosphate binders) and/or by increasing renal phosphate excretion (i.e., use of acetazolamide, probenecid, or niacinamide/nicotinamide); however, clinical responses vary. Surgical resection of tumoral calcinosis lesions &#x02013; generally reserved for those patients with significant pain or functional impairment &#x02013; has variable success. Treatment of pain associated with hyperostosis is symptomatic. No data on management of vascular calcification or testicular microlithiasis are available.</p><p><i>Surveillance:</i> No specific guidelines address the issue of surveillance in HFTC. The frequency of monitoring depends on the clinical findings and medical treatment, as no data support an appropriate monitoring interval.</p><p><i>Agents/circumstances to avoid:</i> It is prudent to avoid: use of calcium salts as phosphate binders; excessive dietary calcium intake; excessive vitamin D intake/supplements; foods high in phosphorus.</p><p><i>Evaluation of relatives at risk:</i> It is appropriate to evaluate apparently asymptomatic older and younger sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures to avoid development of ectopic calcifications.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>HFTC is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Once the <i>FGF23</i>, <i>GALNT3</i>, or <i>KL</i> pathogenic variants have been identified in an affected family member, <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> for at-risk relatives, prenatal testing for a pregnancy at increased risk, and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="hyper-ftc.Diagnosis"><h2 id="_hyper-ftc_Diagnosis_">Diagnosis</h2><div id="hyper-ftc.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Hyperphosphatemic <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> tumoral calcinosis (HFTC) <b>should be suspected</b> in individuals with the following clinical, laboratory, and/or imaging findings.</p><div id="hyper-ftc.Clinical_Findings"><h4>Clinical Findings</h4><p><b>Tumoral calcinosis or ectopic calcifications</b> are typically seen in periarticular soft tissues exposed to repetitive trauma or prolonged pressure, such as the hips, elbows, and shoulders; they can also be observed in other locations ranging from the eyelid [<a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2006.4472">Ichikawa et al 2006</a>] to the submucosa of the large intestines (<a class="figpopup" href="/books/NBK476672/figure/hyper-ftc.F1/?report=objectonly" target="object" rid-figpopup="fighyperftcF1" rid-ob="figobhyperftcF1">Figure 1A&#x00026;D</a>) [<a class="bk_pop" href="#hyper-ftc.REF.ramnitz.2016.1845">Ramnitz et al 2016</a>].</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="fighyperftcF1" co-legend-rid="figlgndhyperftcF1"><a href="/books/NBK476672/figure/hyper-ftc.F1/?report=objectonly" target="object" title="Figure 1" class="img_link icnblk_img figpopup" rid-figpopup="fighyperftcF1" rid-ob="figobhyperftcF1"><img class="small-thumb" src="/books/NBK476672/bin/hyper-ftc-Image001.gif" src-large="/books/NBK476672/bin/hyper-ftc-Image001.jpg" alt="Figure 1. A." /></a><div class="icnblk_cntnt" id="figlgndhyperftcF1"><h4 id="hyper-ftc.F1"><a href="/books/NBK476672/figure/hyper-ftc.F1/?report=objectonly" target="object" rid-ob="figobhyperftcF1">Figure 1</a></h4><p class="float-caption no_bottom_margin">A. Computed tomography (CT) scan showing calcifications in an adult with HFTC including shoulder and hip soft tissue calcifications (white arrows), aortic calcification (dashed arrow), papillary muscle calcification (black arrow), and submucosal gut calcifications <a href="/books/NBK476672/figure/hyper-ftc.F1/?report=objectonly" target="object" rid-ob="figobhyperftcF1">(more...)</a></p></div></div><p><b>Hyperostosis.</b> Some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals experience transient but recurrent episodes of pain in the long bones, typically the tibia, associated with erythema, edema, and warmth of the overlying skin [<a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2007a.1943">Ichikawa et al 2007a</a>, <a class="bk_pop" href="#hyper-ftc.REF.gok.2009.131">Gok et al 2009</a>].</p><p><b>Vascular calcifications</b> occur in both large and small vessels; they are often asymptomatic but can cause symptoms of peripheral vascular insufficiency (e.g., pain, cold extremities, and decreased peripheral pulses). Although rarely the presenting feature, the risk is likely increased over the general population; the true frequency is unknown.</p></div><div id="hyper-ftc.Laboratory_Findings"><h4>Laboratory Findings</h4><ul><li class="half_rhythm"><div class="half_rhythm">Hyperphosphatemia</div></li><li class="half_rhythm"><div class="half_rhythm">Inappropriately increased renal tubular reabsorption of phosphorus (TRP)</div></li><li class="half_rhythm"><div class="half_rhythm">Elevated or inappropriately normal 1,25-dihydroxyvitamin D<sub>3</sub> (1,25D) for the degree of hyperphosphatemia</div></li><li class="half_rhythm"><div class="half_rhythm">Renal function and serum calcium levels typically normal</div></li><li class="half_rhythm"><div class="half_rhythm">Parathyroid hormone levels tend to be at the lower end of the normal range.</div></li><li class="half_rhythm"><div class="half_rhythm">Elevated plasma levels of the C-terminal portion of the phosphate-regulating hormone, fibroblast growth factor 23 (FGF23): measured (in clinical laboratories) by enzyme-linked immunosorbent assay (ELISA) utilizing antibodies that bind to the C-terminal portion of FGF23; detecting the combination of the biologically active intact hormone and the biologically inactive C-terminal fragments</div><div class="half_rhythm">Note: Assays to measure intact FGF23 are currently available in research laboratories only. Intact FGF23 is low or inappropriately normal with <i>FGF23-</i>related HFTC and <i>GALNT3-</i>related HFTC, and elevated with <i>KL-</i>related HFTC.</div></li></ul></div><div id="hyper-ftc.Radiographs"><h4>Radiographs</h4><p><b>Tumoral calcinosis.</b> Radiographs of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> lesions show heterogeneous calcified masses (<a class="figpopup" href="/books/NBK476672/figure/hyper-ftc.F2/?report=objectonly" target="object" rid-figpopup="fighyperftcF2" rid-ob="figobhyperftcF2">Figure 2A&#x00026;B</a>).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="fighyperftcF2" co-legend-rid="figlgndhyperftcF2"><a href="/books/NBK476672/figure/hyper-ftc.F2/?report=objectonly" target="object" title="Figure 2" class="img_link icnblk_img figpopup" rid-figpopup="fighyperftcF2" rid-ob="figobhyperftcF2"><img class="small-thumb" src="/books/NBK476672/bin/hyper-ftc-Image002.gif" src-large="/books/NBK476672/bin/hyper-ftc-Image002.jpg" alt="Figure 2. A&#x00026;B." /></a><div class="icnblk_cntnt" id="figlgndhyperftcF2"><h4 id="hyper-ftc.F2"><a href="/books/NBK476672/figure/hyper-ftc.F2/?report=objectonly" target="object" rid-ob="figobhyperftcF2">Figure 2</a></h4><p class="float-caption no_bottom_margin">A&#x00026;B. Radiographs in a child with hyperphosphatemic familial tumoral calcinosis showing tumoral calcinosis of the lateral proximal femur (A) and elbow (B) C. Radiograph of tibias/fibulas in a child showing hyperostosis with hypermineralization <a href="/books/NBK476672/figure/hyper-ftc.F2/?report=objectonly" target="object" rid-ob="figobhyperftcF2">(more...)</a></p></div></div><p><b>Hyperostosis.</b> When hyperostosis is symptomatic (i.e., causes pain, erythema, edema, and warmth), long-bone radiographs show hypermineralization of cortical bone, patchy sclerosis of the medullary cavities, diaphysitis, and marked periosteal reaction (<a class="figpopup" href="/books/NBK476672/figure/hyper-ftc.F2/?report=objectonly" target="object" rid-figpopup="fighyperftcF2" rid-ob="figobhyperftcF2">Figure 2C</a>) [<a class="bk_pop" href="#hyper-ftc.REF.clarke.1984.643">Clarke et al 1984</a>, <a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2007a.1943">Ichikawa et al 2007a</a>, <a class="bk_pop" href="#hyper-ftc.REF.olauson.2008.929">Olauson et al 2008</a>, <a class="bk_pop" href="#hyper-ftc.REF.gok.2009.131">Gok et al 2009</a>, <a class="bk_pop" href="#hyper-ftc.REF.joseph.2010.63">Joseph et al 2010</a>].</p><p><b>Dental radiographs</b> often show the typical findings of short bulbous roots, obliteration of pulp chambers and root canals, abnormal curvature of the dental roots (known as root dilacerations), thistle-shaped dental pulps, and pulp stones (<a class="figpopup" href="/books/NBK476672/figure/hyper-ftc.F2/?report=objectonly" target="object" rid-figpopup="fighyperftcF2" rid-ob="figobhyperftcF2">Figure 2D&#x00026;E</a>) [<a class="bk_pop" href="#hyper-ftc.REF.foster.2014.7s">Foster et al 2014</a>].</p></div><div id="hyper-ftc.Computed_Tomography_CT"><h4>Computed Tomography (CT)</h4><p><b>Tumoral calcinosis.</b> Although CT is the preferred imaging modality to identify and measure calcifications and changes in size, it carries a risk of radiation exposure and should be used conservatively, especially in children (<a class="figpopup" href="/books/NBK476672/figure/hyper-ftc.F2/?report=objectonly" target="object" rid-figpopup="fighyperftcF2" rid-ob="figobhyperftcF2">Figure 2A&#x00026;B</a>, <a class="figpopup" href="/books/NBK476672/figure/hyper-ftc.F3/?report=objectonly" target="object" rid-figpopup="fighyperftcF3" rid-ob="figobhyperftcF3">Figure 3A</a>).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="fighyperftcF3" co-legend-rid="figlgndhyperftcF3"><a href="/books/NBK476672/figure/hyper-ftc.F3/?report=objectonly" target="object" title="Figure 3" class="img_link icnblk_img figpopup" rid-figpopup="fighyperftcF3" rid-ob="figobhyperftcF3"><img class="small-thumb" src="/books/NBK476672/bin/hyper-ftc-Image003.gif" src-large="/books/NBK476672/bin/hyper-ftc-Image003.jpg" alt="Figure 3. A." /></a><div class="icnblk_cntnt" id="figlgndhyperftcF3"><h4 id="hyper-ftc.F3"><a href="/books/NBK476672/figure/hyper-ftc.F3/?report=objectonly" target="object" rid-ob="figobhyperftcF3">Figure 3</a></h4><p class="float-caption no_bottom_margin">A. CT 3D reconstruction in an adult with HFTC demonstrating bilateral vascular calcifications in superficial femoral arteries (solid arrows) and multifocal sheet-like calcification of the subcutaneous tissues at the level of the distal tibiae and fibulae <a href="/books/NBK476672/figure/hyper-ftc.F3/?report=objectonly" target="object" rid-ob="figobhyperftcF3">(more...)</a></p></div></div><p><b>Vascular calcifications.</b> CT can be particularly helpful in identifying vascular calcifications, which appear hyperattenuated when calcium is present (<a class="figpopup" href="/books/NBK476672/figure/hyper-ftc.F3/?report=objectonly" target="object" rid-figpopup="fighyperftcF3" rid-ob="figobhyperftcF3">Figure 3A, C, D</a>).</p></div></div><div id="hyper-ftc.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of HFTC <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the clinical findings of tumoral calcinosis and/or characteristic laboratory findings of hyperphosphatemia, increased TRP, elevated or inappropriately normal 1,25D levels, and elevated C-terminal FGF23 levels.</p><p>Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants in <i>FGF23</i>, <i>GALNT3</i>, or <i>KL</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (<a class="figpopup" href="/books/NBK476672/table/hyper-ftc.T.molecular_genetic_testing_us/?report=objectonly" target="object" rid-figpopup="fighyperftcTmoleculargenetictestingus" rid-ob="figobhyperftcTmoleculargenetictestingus">Table 1</a>) confirms the diagnosis when clinical and laboratory findings are inconclusive.</p><p>Molecular testing approaches can include <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, or <b>comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Persons with the distinctive findings described in <a href="#hyper-ftc.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#hyper-ftc.Option_1">Option 1</a>), whereas those in whom a specific diagnosis has been elusive are more likely to be diagnosed using comprehensive genomic testing (see <a href="#hyper-ftc.Option_2">Option 2</a>).</p><div id="hyper-ftc.Option_1"><h4>Option 1</h4><p>When the phenotypic and laboratory findings suggest the diagnosis of HFTC, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> is based on the order in which pathogenic variants most commonly occur: <i>GALNT3</i> followed by <i>FGF23</i>, then <i>KL.</i> Sequence analysis of the gene of interest is performed first, followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm">Use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>FGF23</i>, <i>GALNT3</i>, <i>KL</i>, and other genes of interest (see <a href="#hyper-ftc.Differential_Diagnosis">Differential Diagnosis</a>) can be considered. Note: (1) The genes included and the <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of multigene panels vary by laboratory and over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. Thus, clinicians should determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul></div><div id="hyper-ftc.Option_2"><h4>Option 2</h4><p>In the event that the diagnosis of HFTC has not been considered, comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/glossary/def-item/genome-sequencing/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">testing</a> (which includes <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/glossary/def-item/exome-sequencing/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>) is likely to be the diagnostic modality selected. For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="hyper-ftc.T.molecular_genetic_testing_us" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Hyperphosphatemic Familial Tumoral Calcinosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476672/table/hyper-ftc.T.molecular_genetic_testing_us/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hyper-ftc.T.molecular_genetic_testing_us_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants in This Gene</th><th id="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Test Method</th></tr><tr><th headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_3" id="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></th><th headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_3" id="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></th></tr></thead><tbody><tr><td headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FGF23</i></td><td headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12/50&#x000a0;<sup>5,&#x000a0;6</sup></td><td headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8/9&#x000a0;<sup>7</sup></td><td headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/9&#x000a0;<sup>7,&#x000a0;8</sup></td></tr><tr><td headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GALNT3</i></td><td headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">37/50&#x000a0;<sup>5,&#x000a0;9</sup></td><td headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">35/35</td><td headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>KL</i></td><td headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/50&#x000a0;<sup>10</sup></td><td headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 reported&#x000a0;<sup>7,&#x000a0;11</sup></td><td headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3%&#x000a0;<sup>12,&#x000a0;13</sup></td><td headers="hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_2_1 hd_h_hyper-ftc.T.molecular_genetic_testing_us_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hyper-ftc.TF.1.1"><p class="no_margin">See <a href="/books/n/gene/hftc/#hftc.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="hyper-ftc.TF.1.2"><p class="no_margin">See <a href="#hyper-ftc.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="hyper-ftc.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="hyper-ftc.TF.1.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods that may be used include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>5. </dt><dd><div id="hyper-ftc.TF.1.5"><p class="no_margin"><a class="bk_pop" href="#hyper-ftc.REF.rafaelsen.2014.98">Rafaelsen et al [2014]</a></p></div></dd><dt>6. </dt><dd><div id="hyper-ftc.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#hyper-ftc.REF.shah.2014.2235">Shah et al [2014]</a>, <a class="bk_pop" href="#hyper-ftc.REF.keskar.2015.1079">Keskar et al [2015]</a>, <a class="bk_pop" href="#hyper-ftc.REF.jost.2016.2810">Jost et al [2016]</a></p></div></dd><dt>7. </dt><dd><div id="hyper-ftc.TF.1.7"><p class="no_margin"><a href="http://www.hgmd.cf.ac.uk/ac/index.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Human Gene Mutation Database</a></p></div></dd><dt>8. </dt><dd><div id="hyper-ftc.TF.1.8"><p class="no_margin">One large <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> has been reported [<a class="bk_pop" href="#hyper-ftc.REF.shah.2014.2235">Shah et al 2014</a>] (see <a href="#hyper-ftc.Molecular_Genetics">Molecular Genetics</a>, <b><i>FGF23</i></b>)</p></div></dd><dt>9. </dt><dd><div id="hyper-ftc.TF.1.9"><p class="no_margin"><a class="bk_pop" href="#hyper-ftc.REF.krstevska.2012.416">Krstevska et al [2012]</a>, <a class="bk_pop" href="#hyper-ftc.REF.favia.2014.569">Favia et al [2014]</a>, <a class="bk_pop" href="#hyper-ftc.REF.finer.2014.1545">Finer et al [2014]</a>, <a class="bk_pop" href="#hyper-ftc.REF.demellawy.2015.170">Demellawy et al [2015]</a>, <a class="bk_pop" href="#hyper-ftc.REF.masi.2015.438">Masi et al [2015]</a>, <a class="bk_pop" href="#hyper-ftc.REF.vieira.2015.e235">Vieira et al [2015]</a>, <a class="bk_pop" href="#hyper-ftc.REF.jost.2016.2810">Jost et al [2016]</a>, <a class="bk_pop" href="#hyper-ftc.REF.ramnitz.2016.1845">Ramnitz et al [2016]</a></p></div></dd><dt>10. </dt><dd><div id="hyper-ftc.TF.1.10"><p class="no_margin"><a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2007c.2684">Ichikawa et al [2007c]</a></p></div></dd><dt>11. </dt><dd><div id="hyper-ftc.TF.1.11"><p class="no_margin">See <a href="#hyper-ftc.Molecular_Genetics">Molecular Genetics</a>, <b><i>KL.</i></b></p></div></dd><dt>12. </dt><dd><div id="hyper-ftc.TF.1.12"><p class="no_margin">One individual with the typical clinical and biochemical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of HFTC did not have pathogenic variants in either <i>FGF23</i> or <i>GALNT3</i>. Because <i>KL</i> was not tested and FGF23 levels were not reported, it is unknown if this individual had FGF23 resistance [<a class="bk_pop" href="#hyper-ftc.REF.jost.2016.2810">Jost et al 2016</a>].</p></div></dd><dt>13. </dt><dd><div id="hyper-ftc.TF.1.13"><p class="no_margin">One individual with the typical clinical and biochemical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of HFTC did not have pathogenic variants in either <i>FGF23</i> or <i>GALNT3</i>; FGF23 levels were not consistent with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KL</i> [<a class="bk_pop" href="#hyper-ftc.REF.ramnitz.2016.1845">Ramnitz et al 2016</a>].</p></div></dd></dl></div></div></div></div></div></div><div id="hyper-ftc.Clinical_Characteristics"><h2 id="_hyper-ftc_Clinical_Characteristics_">Clinical Characteristics</h2><div id="hyper-ftc.Clinical_Description"><h3>Clinical Description</h3><p>Hyperphosphatemic <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> tumoral calcinosis (HFTC) is characterized most commonly by tumoral calcinosis or ectopic calcifications (typically in periarticular soft tissues exposed to repetitive trauma or prolonged pressure) and hyperostosis (typically manifesting as painful swelling overlying the diaphyses of long bones). Onset of lesions typically occurs in the first two decades of life. The dental <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> unique to HFTC includes enamel hypoplasia, short and bulbous roots, pulp chamber and canal obliterations, and pulp stones. Less frequently reported findings include large and small vessel calcifications, testicular microlithiasis, and angioid streaks of the retina.</p><p>HFTC results from a relative deficiency of or resistance to the phosphate-regulating hormone FGF23, leading to hyperphosphatemia due to increased renal phosphate reabsorption and elevated or inappropriately normal 1,25D production, which promotes gastrointestinal absorption of phosphorus and calcium (for more details see <a href="#hyper-ftc.Pathophysiology">Pathophysiology</a>).</p><p>In a review of the medical literature, <a class="bk_pop" href="#hyper-ftc.REF.rafaelsen.2014.98">Rafaelsen et al [2014]</a> found 56 individuals with HFTC from 35 different families with a molecularly confirmed diagnosis of HFTC (i.e., <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> pathogenic variants in <i>FGF23</i>, <i>GALNT3</i>, or <i>KL</i>).</p><p>Since the <a class="bk_pop" href="#hyper-ftc.REF.rafaelsen.2014.98">Rafaelsen et al [2014]</a> review, 14 additional individuals with <i>GALNT3</i>-associated HFTC [<a class="bk_pop" href="#hyper-ftc.REF.krstevska.2012.416">Krstevska et al 2012</a>, <a class="bk_pop" href="#hyper-ftc.REF.favia.2014.569">Favia et al 2014</a>, <a class="bk_pop" href="#hyper-ftc.REF.finer.2014.1545">Finer et al 2014</a>, <a class="bk_pop" href="#hyper-ftc.REF.demellawy.2015.170">Demellawy et al 2015</a>, <a class="bk_pop" href="#hyper-ftc.REF.masi.2015.438">Masi et al 2015</a>, <a class="bk_pop" href="#hyper-ftc.REF.vieira.2015.e235">Vieira et al 2015</a>, <a class="bk_pop" href="#hyper-ftc.REF.jost.2016.2810">Jost et al 2016</a>, <a class="bk_pop" href="#hyper-ftc.REF.ramnitz.2016.1845">Ramnitz et al 2016</a>] and five individuals with <i>FGF23</i>-associated HFTC [<a class="bk_pop" href="#hyper-ftc.REF.shah.2014.2235">Shah et al 2014</a>, <a class="bk_pop" href="#hyper-ftc.REF.keskar.2015.1079">Keskar et al 2015</a>, <a class="bk_pop" href="#hyper-ftc.REF.jost.2016.2810">Jost et al 2016</a>] have been reported.</p><p>For unknown reasons, the manifestations of HFTC vary among family members with the same pathogenic variants and genetic background and similar biochemical profiles. One member may have profound, extensive tumoral calcinosis while others are symptom free [<a class="bk_pop" href="#hyper-ftc.REF.ramnitz.2016.1845">Ramnitz et al 2016</a>]. Of note, since HFTC has been reported in many pedigrees with multigenerational <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a>, some phenotypic features found in association with HFTC may represent the expression of other <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorders.</p><p><b>Tumoral calcinosis</b> represents ectopic calcification in the skin and/or subcutaneous tissue in periarticular locations consisting primarily of hydroxyapatite [<a class="bk_pop" href="#hyper-ftc.REF.boskey.1983.258">Boskey et al 1983</a>, <a class="bk_pop" href="#hyper-ftc.REF.slavin.1993.788">Slavin et al 1993</a>] and &#x02013; in some reports &#x02013; calcium carbonate [<a class="bk_pop" href="#hyper-ftc.REF.annamunthodo.1960.951">Annamunthodo 1960</a>]. The lesions often occur at sites of repeat trauma and/or pressure, with the lateral hips being the most frequently reported site. However, the clinical spectrum of tumoral calcinosis is widely variable, ranging from no lesions [<a class="bk_pop" href="#hyper-ftc.REF.ramnitz.2016.1845">Ramnitz et al 2016</a>], to <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> eyelid calcifications [<a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2006.4472">Ichikawa et al 2006</a>], to periarticular calcifications of significant size (<a class="figpopup" href="/books/NBK476672/figure/hyper-ftc.F2/?report=objectonly" target="object" rid-figpopup="fighyperftcF2" rid-ob="figobhyperftcF2">Figure 2A&#x00026;B</a>).</p><p>These lesions can be extremely painful and debilitating; some may progress in size, perforate the skin, and drain liquid hydroxyapatite (also known as "milk of calcium"), which is often confused with purulent drainage. Such lesions often heal poorly.</p><p>Depending on the size and location, tumoral calcinosis can significantly impair range of motion or lead to frozen joints.</p><p><b>Hyperostosis</b> typically presents as painful swelling in the areas overlying the diaphyses of the long bones (especially the tibiae), and can be the first observed manifestation of HFTC [<a class="bk_pop" href="#hyper-ftc.REF.clarke.1984.643">Clarke et al 1984</a>, <a class="bk_pop" href="#hyper-ftc.REF.frishberg.2005.33">Frishberg et al 2005</a>, <a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2007a.1943">Ichikawa et al 2007a</a>, <a class="bk_pop" href="#hyper-ftc.REF.olauson.2008.929">Olauson et al 2008</a>, <a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2010.896">Ichikawa et al 2010</a>, <a class="bk_pop" href="#hyper-ftc.REF.joseph.2010.63">Joseph et al 2010</a>, <a class="bk_pop" href="#hyper-ftc.REF.favia.2014.569">Favia et al 2014</a>, <a class="bk_pop" href="#hyper-ftc.REF.jost.2016.2810">Jost et al 2016</a>].</p><p>Some patients experience repeat episodes of diaphysitis (inflammation of the shaft of a long bone) involving a number of sites including the ulna, tibia, metacarpal bones, and radius [<a class="bk_pop" href="#hyper-ftc.REF.clarke.1984.643">Clarke et al 1984</a>, <a class="bk_pop" href="#hyper-ftc.REF.campagnoli.2006b.440">Campagnoli et al 2006b</a>, <a class="bk_pop" href="#hyper-ftc.REF.gok.2009.131">Gok et al 2009</a>].</p><p>Biopsies of hyperostosis lesions demonstrate reactive new bone surrounded by fibroblastic stroma infiltrated with plasma cells, lymphocytes, and polymorphonuclear cells; cultures are negative [<a class="bk_pop" href="#hyper-ftc.REF.clarke.1984.643">Clarke et al 1984</a>, <a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2010.896">Ichikawa et al 2010</a>].</p><p><b>Vascular calcifications,</b> identified in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals ranging in age from three to 58 years, are rarely the presenting feature of HFTC. While the true frequency is unknown, the risk of vascular calcifications in HFTC is likely increased over that of the general population.</p><p>The calcifications are often incidental findings on radiologic studies, and patients are often asymptomatic. Some patients have significant symptoms of peripheral vascular insufficiency such as pain, cold extremities, and decreased peripheral pulses. Small to large vessel calcifications have been identified in variable anatomic locations including the cerebral vasculature, lower-extremity vasculature (<a class="figpopup" href="/books/NBK476672/figure/hyper-ftc.F3/?report=objectonly" target="object" rid-figpopup="fighyperftcF3" rid-ob="figobhyperftcF3">Figure 3A&#x00026;B</a>), coronary arteries (<a class="figpopup" href="/books/NBK476672/figure/hyper-ftc.F3/?report=objectonly" target="object" rid-figpopup="fighyperftcF3" rid-ob="figobhyperftcF3">Figure 3C</a>), mesenteric arteries, renal arteries, carotid arteries, iliac vessels, and aorta [<a class="bk_pop" href="#hyper-ftc.REF.martinez.1990.215">Martinez et al 1990</a>, <a class="bk_pop" href="#hyper-ftc.REF.li_voon_chong.1999.262">Li Voon Chong et al 1999</a>, <a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2007c.2684">Ichikawa et al 2007c</a>, <a class="bk_pop" href="#hyper-ftc.REF.lammoglia.2009.178">Lammoglia &#x00026; Mericq 2009</a>, <a class="bk_pop" href="#hyper-ftc.REF.rafaelsen.2014.98">Rafaelsen et al 2014</a>, <a class="bk_pop" href="#hyper-ftc.REF.masi.2015.438">Masi et al 2015</a>, <a class="bk_pop" href="#hyper-ftc.REF.ramnitz.2016.1845">Ramnitz et al 2016</a>]. The most severe reported consequences of vascular calcifications were below- and above-the-knee amputations in one man and digit amputations in the man's two <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sisters [<a class="bk_pop" href="#hyper-ftc.REF.shah.2014.2235">Shah et al 2014</a>].</p><p><b>Dental <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a></b> characteristic of HFTC includes enamel hypoplasia, short and bulbous roots, pulp chamber and canal obliterations, and pulp stones (<a class="figpopup" href="/books/NBK476672/figure/hyper-ftc.F2/?report=objectonly" target="object" rid-figpopup="fighyperftcF2" rid-ob="figobhyperftcF2">Figure 2D&#x00026;E</a>) [<a class="bk_pop" href="#hyper-ftc.REF.lyles.1985.1093">Lyles et al 1985</a>, <a class="bk_pop" href="#hyper-ftc.REF.burkes.1991.222">Burkes et al 1991</a>, <a class="bk_pop" href="#hyper-ftc.REF.benetpag_s.2005.385">Benet-Pag&#x000e8;s et al 2005</a>, <a class="bk_pop" href="#hyper-ftc.REF.laleye.2008.183">Laleye et al 2008</a>, <a class="bk_pop" href="#hyper-ftc.REF.krstevska.2012.416">Krstevska et al 2012</a>, <a class="bk_pop" href="#hyper-ftc.REF.favia.2014.569">Favia et al 2014</a>].</p><p>Dental findings, reported to be the presenting sign in some individuals [<a class="bk_pop" href="#hyper-ftc.REF.dumitrescu.2009.1273">Dumitrescu et al 2009</a>, <a class="bk_pop" href="#hyper-ftc.REF.vieira.2015.e235">Vieira et al 2015</a>], may be the most common imaging findings of HFTC as they can occur in the absence of calcinosis.</p><p><b>Renal calcifications</b> have been described in two individuals, one of whom had mild impairment in renal function [<a class="bk_pop" href="#hyper-ftc.REF.chefetz.2005.261">Chefetz et al 2005</a>, <a class="bk_pop" href="#hyper-ftc.REF.bergwitz.2009.4267">Bergwitz et al 2009</a>].</p><p><b>Inflammation.</b> The cause and role of inflammation in the pathogenesis of the calcific tumors is unclear. Microscopy of the lesions reveals macrophage engulfment of hydroxyapatite crystals, which probably release inflammatory cytokines, the likely etiology of the observed systemic inflammation [<a class="bk_pop" href="#hyper-ftc.REF.ramnitz.2016.1845">Ramnitz et al 2016</a>].</p><p>Five individuals have had elevated markers of inflammation; i.e., C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR) [<a class="bk_pop" href="#hyper-ftc.REF.garringer.2006.4037">Garringer et al 2006</a>, <a class="bk_pop" href="#hyper-ftc.REF.masi.2009.1190">Masi et al 2009</a>, <a class="bk_pop" href="#hyper-ftc.REF.masi.2015.438">Masi et al 2015</a>, <a class="bk_pop" href="#hyper-ftc.REF.ramnitz.2016.1845">Ramnitz et al 2016</a>]. In one individual clinical symptoms of inflammation included recurrent acute inflammatory polyarthritis of the shoulders, hands, and feet [<a class="bk_pop" href="#hyper-ftc.REF.garringer.2006.4037">Garringer et al 2006</a>]. Two others experienced increased fatigue, inflammation-mediated anemia of chronic disease, and thrombocytosis; one also had intermittent fevers and a cutaneous inflammatory calcific reaction [<a class="bk_pop" href="#hyper-ftc.REF.ramnitz.2016.1845">Ramnitz et al 2016</a>].</p><p><b>Testicular microlithiasis</b> was reported in a boy age 14 years. The ultrasound examination showed increased echogenicity with scattered hyperechogenic lesions. A biopsy of one testicle revealed diffuse intratubular calcifications; oligo-azoospermia was noted on spermiogram [<a class="bk_pop" href="#hyper-ftc.REF.campagnoli.2006b.440">Campagnoli et al 2006b</a>]. Similar findings were reported in a man age 45 years [<a class="bk_pop" href="#hyper-ftc.REF.garringer.2007.2390">Garringer et al 2007</a>].</p><p><b>Angioid streaks of the retina</b> were reported in four individuals with HFTC [<a class="bk_pop" href="#hyper-ftc.REF.mcphaul.1961.488">McPhaul &#x00026; Engel 1961</a>, <a class="bk_pop" href="#hyper-ftc.REF.yancovitch.2011.621">Yancovitch et al 2011</a>]. One had symptomatic sudden onset of blurred vision attributed to choroidal neovascularization secondary to angioid streaks 14 years after the initial diagnosis of HFTC [<a class="bk_pop" href="#hyper-ftc.REF.mcgrath.2010.bcr0520103044">McGrath et al 2010</a>].</p></div><div id="hyper-ftc.Phenotype_Correlations_by_Gene"><h3>Phenotype Correlations by Gene</h3><p>Vascular calcifications appear to be more frequent in persons with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>FGF23</i> <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants (5/12) compared to persons with biallelic <i>GALNT3</i> loss-of-function variants (5/37). However, this observation is limited because not all reported individuals were evaluated for the presence of vascular calcifications.</p></div><div id="hyper-ftc.Pathophysiology"><h3>Pathophysiology</h3><p>Deficiency of or resistance to FGF23 leads to hyperphosphatemia resulting in increased renal phosphate reabsorption and elevated or inappropriately normal 1,25D production, which promotes gastrointestinal absorption of phosphorus and calcium. Thereby increased blood calcium X phosphate product, calculated by multiplying the blood calcium (mg/dL) by the blood phosphate (mg/dL), predisposes to ectopic soft-tissue calcification in tissues exposed to trauma or inflammation. In persons with renal insufficiency (where this product is most commonly clinically utilized), the incidence of soft-tissue calcification is increased when the calcium X phosphate product exceeds 70 mg<sup>2</sup>/dL<sup>2</sup> and decreased when the calcium X phosphate product is less than 50 mg<sup>2</sup>/dL<sup>2</sup> [<a class="bk_pop" href="#hyper-ftc.REF.langman.2005">Langman &#x00026; Salusky 2005</a>].</p></div><div id="hyper-ftc.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>No <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> are known.</p><ul><li class="half_rhythm"><div>Sibs with the same <i>GALNT3</i> pathogenic variants have been reported to have markedly different clinical courses [<a class="bk_pop" href="#hyper-ftc.REF.ramnitz.2016.1845">Ramnitz et al 2016</a>].</div></li><li class="half_rhythm"><div>Treatment response does not appear to vary by <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>.</div></li></ul></div><div id="hyper-ftc.Nomenclature"><h3>Nomenclature</h3><p>In the past, hyperphosphatemic <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> tumoral calcinosis (HFTC) has been referred to as the following:</p><ul><li class="half_rhythm"><div>Lipocalcinogranulomatosis</div></li><li class="half_rhythm"><div>Teutschlaender's lipocalcinogranulomatosis</div></li><li class="half_rhythm"><div>Morbus Teutschl&#x000e4;nder</div></li></ul></div><div id="hyper-ftc.Prevalence"><h3>Prevalence</h3><p>No formal study has estimated the prevalence of HFTC; the disorder is rare. To date, 75 individuals with a molecularly confirmed diagnosis of HFTC have been reported in the medical literature with an increased propensity in Africa and the Middle East and in populations originating from these regions [<a class="bk_pop" href="#hyper-ftc.REF.sprecher.2010.652">Sprecher 2010</a>].</p></div></div><div id="hyper-ftc.Genetically_Related_Allelic_Di"><h2 id="_hyper-ftc_Genetically_Related_Allelic_Di_">Genetically Related (Allelic) Disorders</h2><p>Heterozygous <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> pathogenic variants in <i>FGF23</i> are also associated with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> hypophosphatemic rickets, a disorder with the opposite biochemical findings of HFTC (OMIM <a href="https://omim.org/entry/193100" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">193100</a>).</p><p>A balanced <a class="def" href="/books/n/gene/glossary/def-item/translocation/">translocation</a> t(9:13)(q21.13;q13.1) that results in <i>KL</i> <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> was identified in an individual with hypophosphatemic rickets and hyperparathyroidism (also biochemically opposite to HFTC) (OMIM <a href="https://omim.org/entry/612089" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">612089</a>).</p><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with intragenic pathogenic variants in <i>GALNT3</i> or <i>KL</i>.</p></div><div id="hyper-ftc.Differential_Diagnosis"><h2 id="_hyper-ftc_Differential_Diagnosis_">Differential Diagnosis</h2><div id="hyper-ftc.T.genetic_disorders_to_conside" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Genetic Disorders to Consider in the Differential Diagnosis of Hyperphosphatemic Familial Tumoral Calcinosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476672/table/hyper-ftc.T.genetic_disorders_to_conside/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hyper-ftc.T.genetic_disorders_to_conside_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_1" rowspan="3" scope="col" colspan="1" headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_2" rowspan="3" scope="col" colspan="1" headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_3" rowspan="3" scope="col" colspan="1" headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4" colspan="3" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Features of This Disorder</th></tr><tr><th headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_1" id="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_1" rowspan="2" colspan="1" scope="colgroup" style="text-align:left;vertical-align:middle;">Overlapping w/HFTC</th><th headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4" id="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Distinguishing from HFTC</th></tr><tr><th headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2" id="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Biochemical</th><th headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2" id="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical</th></tr></thead><tbody><tr><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/porphyria-ct/">Porphyria cutanea tarda</a></td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>UROD</i></td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Dystrophic calcification in areas of pseudoscleroderma</div></li><li class="half_rhythm"><div>Ulcerated areas at pseudoscleroderma sites in some</div></li></ul>
</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal blood phosphorus</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Blistering &#x00026; skin fragility w/sun exposure</div></li><li class="half_rhythm"><div>Hypertrichosis/ hyperpigmentation</div></li><li class="half_rhythm"><div>Pseudoscleroderma</div></li><li class="half_rhythm"><div>Increased urinary excretion of uroporphyrin</div></li></ul>
</td></tr><tr><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normophosphatemic<br /><a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> tumoral<br />calcinosis<br />(OMIM <a href="https://omim.org/entry/610455" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">610455</a>)</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SAMD9</i></td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Skin/subcutaneous calcinosis</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Normal blood phosphorus</div></li><li class="half_rhythm"><div>Normal renal &#x00026; intestinal reabsorption of phosphorus</div></li></ul>
</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Calcification often preceded by inflammatory rash</div></li><li class="half_rhythm"><div>Lesions found in acral locations rather than periarticular</div></li><li class="half_rhythm"><div>Severe conjunctivitis &#x00026; gingivitis</div></li></ul>
</td></tr><tr><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pseudohypopara-<br />thyroidism 1a, 1b, 1c<br />(see <a href="/books/n/gene/gnas-dis/">Disorders of <i>GNAS</i> Inactivation</a>)</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GNAS</i></td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 1</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Elevated blood phosphorus</div></li><li class="half_rhythm"><div>Subcutaneous ossifications</div></li></ul>
</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Elevated blood parathyroid hormone due to end-organ resistance</div></li><li class="half_rhythm"><div>Low blood calcium, obesity</div></li><li class="half_rhythm"><div>Resistance to other hormones incl TSH, LH/FSH, GHRH</div></li></ul>
</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical features of Albright hereditary osteodystrophy incl short stature, round facies, brachydactyly, other skeletal anomalies</td></tr><tr><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pseudopseudohypo-<br />parathyroidism (see<br /><a href="/books/n/gene/gnas-dis/">Disorders of <i>GNAS</i> Inactivation</a>)</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GNAS</i></td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 1</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Subcutaneous ossifications</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal blood phosphorus, parathyroid hormone, calcium</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical features of Albright hereditary osteodystrophy incl short stature, round facies, brachydactyly, other skeletal anomalies</td></tr><tr><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progressive osseous<br />heteroplasia (see<br /><a href="/books/n/gene/gnas-dis/">Disorders of <i>GNAS</i> Inactivation</a>)</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GNAS</i></td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 1</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Subcutaneous ossifications</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal blood phosphorus, parathyroid hormone, calcium</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Infantile onset of subcutaneous ossifications</div></li><li class="half_rhythm"><div>Congenital papular rash</div></li></ul>
</td></tr><tr><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Fibrodysplasia ossificans progressiva<br />(OMIM <a href="https://omim.org/entry/135100" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">135100</a>)</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ACVR1</i></td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Subcutaneous ossifications that can impair joint mobility</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal blood phosphorus</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Gradual replacement of muscle tissue &#x00026; connective tissue by bone starting w/neck &#x00026; shoulders &#x00026; proceeding down the body</div></li><li class="half_rhythm"><div>Typically, malformed big toes</div></li></ul>
</td></tr><tr><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/gaci/">Generalized arterial calcification of infancy</a></td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ABCC6</i><br /><i>ENPP1</i></td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Extravascular periarticular calcifications</div></li><li class="half_rhythm"><div>May have angioid streaks of the retina</div></li></ul>
</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal or low blood phosphorus (some develop hypophosphatemic rickets after infancy)</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Extensive medium- &#x00026; large-artery calcification in infancy resulting in cardiovascular findings</div></li><li class="half_rhythm"><div>May have yellow papules in flexural body areas</div></li><li class="half_rhythm"><div>Hearing loss</div></li></ul>
</td></tr><tr><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cole disease<br />(OMIM <a href="https://omim.org/entry/615522" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615522</a>)</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ENPP1</i></td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Skin/subcutaneous calcinosis</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal blood phosphorus</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Congenital or early-onset punctate keratoderma of palms &#x00026; soles</div></li><li class="half_rhythm"><div>Diffuse, irregularly shaped hypopigmented skin macules typically over arms &#x00026; legs</div></li><li class="half_rhythm"><div>May have calcific tendinopathy</div></li></ul>
</td></tr><tr><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Arterial calcification due<br />to CD73 deficiency<br />(OMIM <a href="https://omim.org/entry/211800" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">211800</a>)</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NT5E</i></td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Periarticular calcifications of large &#x00026; small joints of lower extremities</div></li><li class="half_rhythm"><div>Symptomatic calcification of the large arteries of lower extremities</div></li></ul>
</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal blood phosphorus</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically present w/claudication &#x00026; hemodynamically significant peripheral obstructive artery disease of lower extremities</td></tr><tr><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/caffey/">Caffey disease</a></td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>COL1A1</i></td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cortical hyperostosis of long bones</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal blood phosphorus</td><td headers="hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_1_4 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_2_2 hd_h_hyper-ftc.T.genetic_disorders_to_conside_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Onset between birth &#x00026; 5 mos; spontaneous resolution by age 2 yrs</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></p></div></dd><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a></p></div></dd><dt></dt><dd><div><p class="no_margin">AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a></p></div></dd><dt>1. </dt><dd><div id="hyper-ftc.TF.2.1"><p class="no_margin"><a href="/books/n/gene/gnas-dis/">Disorders of <i>GNAS</i> inactivation</a> are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner with parental <a class="def" href="/books/n/gene/glossary/def-item/imprinting/">imprinting</a>.</p></div></dd></dl></div></div></div><p>Table 3. Acquired Disorders to Consider in the Differential Diagnosis of Hyperphosphatemic Familial Tumoral Calcinosis</p><div id="hyper-ftc.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476672/table/hyper-ftc.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hyper-ftc.Td_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hyper-ftc.Td_1_1_1_1" rowspan="3" scope="col" colspan="1" headers="hd_h_hyper-ftc.Td_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_hyper-ftc.Td_1_1_1_2" colspan="3" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Clinical Features of the Disorder</th></tr><tr><th headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_1" id="hd_h_hyper-ftc.Td_1_1_2_1" rowspan="2" colspan="1" scope="colgroup" style="text-align:left;vertical-align:middle;">Overlapping w/HFTC</th><th headers="hd_h_hyper-ftc.Td_1_1_1_2" id="hd_h_hyper-ftc.Td_1_1_2_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Distinguishing from HFTC</th></tr><tr><th headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_2" id="hd_h_hyper-ftc.Td_1_1_3_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Biochemical</th><th headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_2" id="hd_h_hyper-ftc.Td_1_1_3_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical</th></tr></thead><tbody><tr><td headers="hd_h_hyper-ftc.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Osteomyelitis&#x000a0;<sup>1</sup></td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Erythema, warmth, &#x00026; diaphyseal pain of the long bones</div></li><li class="half_rhythm"><div>Fever</div></li><li class="half_rhythm"><div>Ulceration &#x00026; drainage of skin</div></li><li class="half_rhythm"><div>Elevated inflammatory markers (ESR/CRP)</div></li></ul>
</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_2 hd_h_hyper-ftc.Td_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Normal blood phosphorus</div></li><li class="half_rhythm"><div>Blood cultures may be positive</div></li><li class="half_rhythm"><div>Positive bacterial culture from bone biopsy obtained via sterile technique</div></li></ul>
</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_2 hd_h_hyper-ftc.Td_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Distinct radiographic features of osteomyelitis</div></li><li class="half_rhythm"><div>Distinct histopathologic features following biopsy</div></li><li class="half_rhythm"><div>May present as septic arthritis</div></li></ul>
</td></tr><tr><td headers="hd_h_hyper-ftc.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Autoimmune connective tissue disease</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Skin/subcutaneous calcinosis</div></li><li class="half_rhythm"><div>Calcinosis can occur over joints leading to functional impairment.</div></li><li class="half_rhythm"><div>Ulcerated areas can occur at sites of calcinosis.</div></li><li class="half_rhythm"><div>Elevated inflammatory markers (ESR/CRP)</div></li></ul>
</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_2 hd_h_hyper-ftc.Td_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal blood phosphorus</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_2 hd_h_hyper-ftc.Td_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Other features of dermatomyositis (proximal muscle weakness, interstitial pulmonary disease, dysphagia, polyarthritis, Gottron's papules, heliotrope eruption)</div></li><li class="half_rhythm"><div>Other features of systemic sclerosis (arthralgia, myalgia, skin thickening/hardening, sclerodactyly, Raynaud phenomenon, esophageal dysmotility, telangiectasia, &#x00026; pulmonary, renal, or cardiac disease)</div></li><li class="half_rhythm"><div>Other features of systemic lupus erythematosus (arthralgia, myalgia, fever, malar erythema, Raynaud phenomenon, vasculitis, &#x00026; thromboembolic, pulmonary, renal, cardiac, or ophthalmologic disease)</div></li></ul>
</td></tr><tr><td headers="hd_h_hyper-ftc.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Panniculitis</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Skin/subcutaneous calcinosis</div></li><li class="half_rhythm"><div>Ulcerated areas can occur at sites of calcinosis.</div></li></ul>
</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_2 hd_h_hyper-ftc.Td_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal blood phosphorus</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_2 hd_h_hyper-ftc.Td_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Other features of pancreatic disease in pancreatic panniculitis (pancreatitis, elevated amylase/lipase)</div></li><li class="half_rhythm"><div>Other features of subcutaneous fat necrosis of newborn (presents during 1st few weeks of life, typically history of trauma during delivery; may develop hypercalcemia)</div></li></ul>
</td></tr><tr><td headers="hd_h_hyper-ftc.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Trauma</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Skin/subcutaneous calcinosis</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_2 hd_h_hyper-ftc.Td_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal blood phosphorus</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_2 hd_h_hyper-ftc.Td_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">History of prior tissue injury (e.g., burns, trauma, surgery)</td></tr><tr><td headers="hd_h_hyper-ftc.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Infection</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Skin/subcutaneous calcinosis</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_2 hd_h_hyper-ftc.Td_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal blood phosphorus</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_2 hd_h_hyper-ftc.Td_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Other symptoms of onchocerciasis (river blindness) &#x00026; travel to endemic areas (sub-Saharan Africa)</div></li><li class="half_rhythm"><div>Other symptoms of cysticercosis &#x00026; ingestion of undercooked meat</div></li></ul>
</td></tr><tr><td headers="hd_h_hyper-ftc.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chronic renal failure</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Elevated blood phosphorus</div></li><li class="half_rhythm"><div>Low blood 1,25D levels</div></li></ul>
</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_2 hd_h_hyper-ftc.Td_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">May have decreased blood calcium &#x00026; secondary hyperparathyroidism</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_2 hd_h_hyper-ftc.Td_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Biochemical evidence of renal insufficiency (elevated creatinine &#x00026; BUN)</td></tr><tr><td headers="hd_h_hyper-ftc.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Iatrogenic calcinosis cutis</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Skin/subcutaneous calcinosis</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_2 hd_h_hyper-ftc.Td_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal blood phosphorus</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_2 hd_h_hyper-ftc.Td_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">History of extravasation of intravenous solutions (e.g., calcium gluconate, calcium chloride, or phosphate-containing solutions at site of calcinosis)</td></tr><tr><td headers="hd_h_hyper-ftc.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypervitaminosis D</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Skin/subcutaneous calcinosis</div></li><li class="half_rhythm"><div>Low blood 1,25D levels</div></li></ul>
</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_2 hd_h_hyper-ftc.Td_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Normal or low blood phosphorus</div></li><li class="half_rhythm"><div>Elevated blood calcium &#x00026; renal calcium excretion</div></li><li class="half_rhythm"><div>Elevated 25-OH vitamin D</div></li></ul>
</td><td headers="hd_h_hyper-ftc.Td_1_1_1_2 hd_h_hyper-ftc.Td_1_1_2_2 hd_h_hyper-ftc.Td_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Symptoms of hypercalcemia incl polyuria, polydipsia, confusion, anorexia, vomiting, muscle weakness</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hyper-ftc.TF.d.1"><p class="no_margin">Hyperostosis is often misdiagnosed as osteomyelitis resulting in unnecessary long-term treatment with intravenous antibiotics.</p></div></dd></dl></div></div></div></div><div id="hyper-ftc.Management"><h2 id="_hyper-ftc_Management_">Management</h2><div id="hyper-ftc.Evaluations_Following_Initial"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with hyperphosphatemic <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> tumoral calcinosis (HFTC), the following evaluations are recommended if not done at the time of diagnosis:</p><ul><li class="half_rhythm"><div class="half_rhythm">Physical examination with particular attention to:</div><ul><li class="half_rhythm"><div>Skin and joints to assess for tumoral calcinosis;</div></li><li class="half_rhythm"><div>Lower extremities to assess for edema, erythema, and pain related to hyperostosis;</div></li><li class="half_rhythm"><div>Peripheral pulses to assess for clinically significant vascular calcification.</div></li></ul><div class="half_rhythm">Use ankle-brachial systolic pressure index to confirm clinical suspicion of lower-extremity arterial occlusive disease.</div></li><li class="half_rhythm"><div class="half_rhythm">Metabolic work up including blood phosphorus, blood creatinine, urine phosphorus, urine creatinine to evaluate renal phosphate handling by measuring the tubular reabsorption of phosphorus (TRP) and the ratio of the renal tubular maximum reabsorption rate of phosphate to the glomerular filtration rate (TmP/GFR)</div></li><li class="half_rhythm"><div class="half_rhythm">Duplex ultrasound examination, CT angiography, and/or magnetic resonance angiography (<a class="figpopup" href="/books/NBK476672/figure/hyper-ftc.F3/?report=objectonly" target="object" rid-figpopup="fighyperftcF3" rid-ob="figobhyperftcF3">Figure 3B</a>) to evaluate for vascular calcifications if there is a history of claudication or atypical leg symptoms, or clinical signs of vascular disease on physical examination (e.g., diminished pulses or cold extremities)</div></li><li class="half_rhythm"><div class="half_rhythm">Cardiac CT angiography (<a class="figpopup" href="/books/NBK476672/figure/hyper-ftc.F3/?report=objectonly" target="object" rid-figpopup="fighyperftcF3" rid-ob="figobhyperftcF3">Figure 3C&#x00026;D</a>) to assess for coronary artery calcifications particularly in patients with documented vascular calcifications</div></li><li class="half_rhythm"><div class="half_rhythm">Consultation with a vascular specialist and/or cardiologist for patients with symptomatic vascular calcifications</div></li><li class="half_rhythm"><div class="half_rhythm">Complete blood count, erythrocyte sedimentation rate, and C-reactive protein to evaluate for evidence of systemic inflammation</div></li><li class="half_rhythm"><div class="half_rhythm">Dental consultation including dental radiographs to assess for the HFTC dental <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (<a class="figpopup" href="/books/NBK476672/figure/hyper-ftc.F2/?report=objectonly" target="object" rid-figpopup="fighyperftcF2" rid-ob="figobhyperftcF2">Figure 2D&#x00026;E</a>)</div></li><li class="half_rhythm"><div class="half_rhythm">Testicular ultrasound examination to assess for microlithiasis (<a class="figpopup" href="/books/NBK476672/figure/hyper-ftc.F1/?report=objectonly" target="object" rid-figpopup="fighyperftcF1" rid-ob="figobhyperftcF1">Figure 1C</a>)</div></li><li class="half_rhythm"><div class="half_rhythm">Renal ultrasound examination to evaluate for medullary nephrocalcinosis</div></li><li class="half_rhythm"><div class="half_rhythm">Ophthalmologic consultation to evaluate for eyelid calcifications and angioid streaks of the retina</div></li><li class="half_rhythm"><div class="half_rhythm">Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="hyper-ftc.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>No standard treatment for HFTC exists. No randomized clinical trials have been performed, and studies of the treatment of HFTC consist of case reports or case series.</p><p>Most reported therapies attempt to lower blood phosphorus; most patients with HFTC are treated with a combination of medical therapies. Clinical response to these treatments varies. No treatment regimen appears to consistently or universally decrease lesion size or prevent progression or recurrence of lesions after surgery.</p><p><b>Tumoral calcinosis</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Low-phosphate diet. Many patients are instructed to follow a low-phosphate diet in combination with other medical therapies. Limited benefit was reported in use of low-phosphate diet alone [<a class="bk_pop" href="#hyper-ftc.REF.carmichael.2009.664">Carmichael et al 2009</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Phosphate binders, such as sevelamer and aluminum hydroxide, are used to decrease absorption of dietary phosphorus. Response is mixed, including: (1) decrease or no change in blood phosphorus; (2) decrease, no change, or increase in the size of the tumoral calcinosis [<a class="bk_pop" href="#hyper-ftc.REF.steinherz.1985.816">Steinherz et al 1985</a>, <a class="bk_pop" href="#hyper-ftc.REF.yamaguchi.1995.247s">Yamaguchi et al 1995</a>, <a class="bk_pop" href="#hyper-ftc.REF.campagnoli.2006a.188">Campagnoli et al 2006a</a>, <a class="bk_pop" href="#hyper-ftc.REF.garringer.2006.4037">Garringer et al 2006</a>, <a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2007b.318">Ichikawa et al 2007b</a>, <a class="bk_pop" href="#hyper-ftc.REF.lammoglia.2009.178">Lammoglia and Mericq 2009</a>, <a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2010.896">Ichikawa et al 2010</a>, <a class="bk_pop" href="#hyper-ftc.REF.finer.2014.1545">Finer et al 2014</a>, <a class="bk_pop" href="#hyper-ftc.REF.keskar.2015.1079">Keskar et al 2015</a>, <a class="bk_pop" href="#hyper-ftc.REF.ramnitz.2016.1845">Ramnitz et al 2016</a>].</div><div class="half_rhythm">Note: (1) Aluminum-containing phosphate binders can probably be used safely in patients with HFTC as opposed to patients with renal failure, in whom the risk of aluminum toxicity is increased due to impaired renal clearance. (2) Calcium salts, used in the past, have fallen out of favor because of their potential to increase the calcium X phosphate product, as defined in <a href="#hyper-ftc.Pathophysiology">Pathophysiology</a>.</div></li><li class="half_rhythm"><div class="half_rhythm">Acetazolamide, a carbonic anhydrase inhibitor, increases urinary phosphate excretion. While some reports describe improvement or resolution of tumoral calcinosis following treatment with acetazolamide alone or &#x02013; most often &#x02013; in combination with phosphate binders, other reports describe no change in lesions. Similarly, blood phosphorus levels decreased or remained unchanged [<a class="bk_pop" href="#hyper-ftc.REF.yamaguchi.1995.247s">Yamaguchi et al 1995</a>, <a class="bk_pop" href="#hyper-ftc.REF.garringer.2006.4037">Garringer et al 2006</a>, <a class="bk_pop" href="#hyper-ftc.REF.dumitrescu.2009.1273">Dumitrescu et al 2009</a>, <a class="bk_pop" href="#hyper-ftc.REF.lammoglia.2009.178">Lammoglia &#x00026; Mericq 2009</a>, <a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2010.896">Ichikawa et al 2010</a>, <a class="bk_pop" href="#hyper-ftc.REF.finer.2014.1545">Finer et al 2014</a>, <a class="bk_pop" href="#hyper-ftc.REF.ramnitz.2016.1845">Ramnitz et al 2016</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Probenecid (which promotes renal phosphate excretion) has been used along with other phosphate-lowering medications. Note: Because probenecid prolongs the half-life of a number of drugs, physicians should assess for drug interactions prior to starting this medication.</div><ul><li class="half_rhythm"><div>Treatment with probenecid did not decrease blood phosphorus or improve clinical status in two individuals [<a class="bk_pop" href="#hyper-ftc.REF.mcphaul.1961.488">McPhaul &#x00026; Engel 1961</a>, <a class="bk_pop" href="#hyper-ftc.REF.lammoglia.2009.178">Lammoglia &#x00026; Mericq 2009</a>].</div></li><li class="half_rhythm"><div>Following surgical resection of tumoral calcinosis, one individual was recurrence free after six years of probenecid and phosphate binder therapy, despite no change in blood phosphate [<a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2010.896">Ichikawa et al 2010</a>].</div></li><li class="half_rhythm"><div>In one series, treatment that included probenecid was associated with complete resolution of tumoral calcinosis in one patient but no change in the size of lesions in others [<a class="bk_pop" href="#hyper-ftc.REF.ramnitz.2016.1845">Ramnitz et al 2016</a>].</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm">Niacinamide/nicotinamide, shown to decrease renal phosphate reabsorption, has been evaluated as a short-term treatment in two patients: one showed decreased blood phosphorus during a 48-hour treatment [<a class="bk_pop" href="#hyper-ftc.REF.dumitrescu.2009.1273">Dumitrescu et al 2009</a>]; one showed no change in blood phosphorus during an approximately three-week treatment [<a class="bk_pop" href="#hyper-ftc.REF.ramnitz.2016.1845">Ramnitz et al 2016</a>]. Of note, there are no long-term treatment data.</div></li><li class="half_rhythm"><div class="half_rhythm">Topical sodium thiosulfate applied to skin overlying the tumoral calcinosis lesions has been shown to decrease ectopic calcifications after at least five months of treatment in three patients [<a class="bk_pop" href="#hyper-ftc.REF.jost.2016.2810">Jost et al 2016</a>]. The mechanism by which topical or systemic sodium thiosulfate inhibits mineralization is unclear.</div></li><li class="half_rhythm"><div class="half_rhythm">Risedronate, a bisphosphonate with anti-osteoclast activity, was used in one patient for one year, after which no change in blood phosphorus level or obvious improvement in tumoral calcinosis burden was observed [<a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2010.896">Ichikawa et al 2010</a>]. Of note, there is no mechanistic support for the use of second-generation bisphosphonates in the treatment of HFTC.</div></li><li class="half_rhythm"><div class="half_rhythm">Synthetic salmon calcitonin, a hormone that inhibits osteoclast activity and rental tubular reabsorption of calcium and phosphorus, was administered subcutaneously to one patient in combination with a low-phosphate diet and phosphate binder. The patient had a decrease in blood phosphorus on treatment; tumoral calcinosis lesions remained stable in size while no new ectopic calcifications developed [<a class="bk_pop" href="#hyper-ftc.REF.candrina.1989.55">Candrina et al 1989</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Surgical resection of tumoral calcinosis lesions has variable outcomes. Some patients have complete resolution of the lesions while others have required multiple surgeries due to lesion recurrence [<a class="bk_pop" href="#hyper-ftc.REF.carmichael.2009.664">Carmichael et al 2009</a>, <a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2010.896">Ichikawa et al 2010</a>, <a class="bk_pop" href="#hyper-ftc.REF.ramnitz.2016.1845">Ramnitz et al 2016</a>]. Given the risks of surgical morbidities and recurrence of lesions, surgical resection of tumoral calcinosis may be reserved for those with significant pain or functional impairment.</div></li></ul><p><b>Hyperostosis</b></p><ul><li class="half_rhythm"><div>Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used to treat the pain and edema associated with hyperostosis [<a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2007a.1943">Ichikawa et al 2007a</a>].</div></li><li class="half_rhythm"><div>Acetaminophen in combination with NSAIDs has been shown to improve the symptoms of hyperostosis [<a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2010.896">Ichikawa et al 2010</a>].</div></li><li class="half_rhythm"><div>Steroids &#x02013; prescribed for a brief course in one patient with hyperostosis &#x02013; reduced edema [<a class="bk_pop" href="#hyper-ftc.REF.masi.2015.438">Masi et al 2015</a>].</div></li></ul><p><b>Vascular calcification</b></p><ul><li class="half_rhythm"><div>No data are available on the management of vascular calcification in HFTC.</div></li><li class="half_rhythm"><div>Patients with vascular calcification should be evaluated by a vascular specialist and/or cardiologist for further assessment and treatment including optimizing other modifiable cardiovascular risk factors.</div></li></ul><p><b>Systemic inflammation.</b> Interleukin-1 (IL-1) antagonists (canakinumab, a monoclonal IL-1&#x003b2; antibody; or anakinra, a recombinant IL-1 receptor antagonist) were used to treat two patients with overwhelming systemic inflammation after one patient failed treatment with NSAIDs and glucocorticoids. In both, inflammatory markers significantly decreased; in one, calcinosis cutis resolved and perilesional edema of hip tumoral calcinosis improved. Both subjectively reported improved energy, appetite, and overall sense of well-being [<a class="bk_pop" href="#hyper-ftc.REF.ramnitz.2016.1845">Ramnitz et al 2016</a>].</p><p><b>Dental abnormalities.</b> Patients should receive routine dental care.</p><p><b>Testicular microlithiasis</b></p><ul><li class="half_rhythm"><div>No data are available on the management of testicular microlithiasis.</div></li><li class="half_rhythm"><div>Men with impaired fertility may be referred to a reproductive specialist for further evaluation.</div></li></ul><p><b>Angioid streaks</b></p><ul><li class="half_rhythm"><div>Patients should be referred to an ophthalmologist for evaluation, treatment, and monitoring of angioid streaks of the retina.</div></li><li class="half_rhythm"><div>Intravitrial ranibizumab injections improved visual acuity in the only individual reported to experience sudden worsening of vision due to choroidal neovascularization associated with an angioid streak [<a class="bk_pop" href="#hyper-ftc.REF.mcgrath.2010.bcr0520103044">McGrath et al 2010</a>].</div></li></ul></div><div id="hyper-ftc.Surveillance"><h3>Surveillance</h3><p>No specific guidelines address the issue of surveillance in HFTC. The frequency of monitoring depends on clinical findings and medical treatment, as there are no data to support an appropriate monitoring interval.</p><p><b>Tumoral calcinosis.</b> When initiating medical therapy the following should be monitored regularly:</p><ul><li class="half_rhythm"><div>Blood phosphorus to help manage medication doses</div></li><li class="half_rhythm"><div>Blood calcium and intact parathyroid hormone because levels of 1,25D can be elevated</div></li><li class="half_rhythm"><div>Complete blood count, ESR, and CRP to assess for evidence of inflammation</div></li><li class="half_rhythm"><div>Renal function because hyperphosphatemia can contribute to development of kidney disease</div></li></ul><p>In patients treated with acetazolamide, blood chemistries to assess for evidence of metabolic acidosis.</p><p>In patients treated with probenecid, blood uric acid levels to help manage medication doses. Probenecid should be increased until the blood uric acid level is suppressed or the maximum dose for age is reached.</p><p>Radiographs of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> areas can be performed intermittently to evaluate and assess the presence or change in size of lesions of tumoral calcinosis (with the goal of minimizing radiation exposure).</p><p><b>Hyperostosis.</b> Routine surveillance of hyperostosis without clinical symptoms is unnecessary; however, if long-bone pain, erythema, and/or edema develop, obtain radiographs to assess for hyperostosis.</p><p><b>Vascular calcifications.</b> No data are available regarding surveillance for vascular calcifications.</p><p><b>Dental abnormalities.</b> Provide dental surveillance as part of routine dental care.</p><p><b>Testicular microlithiasis.</b> No data are available regarding surveillance for testicular microlithiasis.</p><p><b>Angioid streaks of the retina.</b> Patients with angioid streaks of the retina should be followed by an ophthalmologist.</p></div><div id="hyper-ftc.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Because phosphorus-lowering medications are aimed at lowering the calcium X phosphate product, it is prudent to avoid the following:</p><ul><li class="half_rhythm"><div>Use of calcium salts as phosphate binders</div></li><li class="half_rhythm"><div>Excessive dietary calcium intake</div></li><li class="half_rhythm"><div>Excessive vitamin D intake and/or supplements</div></li><li class="half_rhythm"><div>Foods high in phosphorus</div></li></ul></div><div id="hyper-ftc.Evaluation_of_Relatives_at_Ris"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate apparently asymptomatic older and younger sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.</p><p>Evaluations can include:</p><ul><li class="half_rhythm"><div>Blood phosphorus, the most cost-effective approach</div></li><li class="half_rhythm"><div>Molecular genetic testing if the pathogenic variants in the family are known</div></li><li class="half_rhythm"><div>Evaluation of phosphorus and calcium metabolism including blood phosphorus, blood creatinine, blood calcium, parathyroid hormone, 1,25D, 25-OH vitamin D, C-terminal FGF23, urine phosphorus, and urine creatinine if initial blood phosphorus level is inconclusive or if the pathogenic variants in the family are not known</div></li></ul><p>See <a href="#hyper-ftc.Related_Genetic_Counseling_Iss">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="hyper-ftc.Pregnancy_Management"><h3>Pregnancy Management</h3><p>While there is a lack of information regarding pregnancies in women with HFTC, calcifications of the placenta have been noted post delivery [<a class="bk_pop" href="#hyper-ftc.REF.li_voon_chong.1999.262">Li Voon Chong et al 1999</a>, <a class="bk_pop" href="#hyper-ftc.REF.mcgrath.2010.bcr0520103044">McGrath et al 2010</a>]. Therefore, pregnancy is best managed by a specialist in high-risk maternal-fetal obstetrics.</p></div><div id="hyper-ftc.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="hyper-ftc.Genetic_Counseling"><h2 id="_hyper-ftc_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="hyper-ftc.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Hyperphosphatemic <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> tumoral calcinosis (HFTC) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="hyper-ftc.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The normophosphatemic parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>FGF23</i>, <i>GALNT3</i>, or <i>KL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder; however, one <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> from a large kindred with HFTC was reported to have hyperphosphatemia and elevated 1,25D without calcinosis lesions [<a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2005.2420">Ichikawa et al 2005</a>].</div></li><li class="half_rhythm"><div>Rarely, when there is <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a> this <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> condition can be reported in consecutive generations.</div></li></ul><p><b>Siblings of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Because of intrafamilial clinical variability, it is not possible to predict the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in sibs who have inherited <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants (see <a href="#hyper-ftc.Clinical_Description">Clinical Description</a>).</div></li><li class="half_rhythm"><div>Although heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder, one <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> from a large kindred with HFTC was reported to have hyperphosphatemia and elevated 1,25D without calcinosis lesions [<a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2005.2420">Ichikawa et al 2005</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Unless an individual with HFTC has children with an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual or a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, his/her offspring will be obligate heterozygotes (carriers) for an <i>FGF23</i>, <i>GALNT3</i>, or <i>KL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>HFTC has been reported in many families with multigenerational <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a>. Consanguinity increases the likelihood that an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual may have a reproductive partner who is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for pathogenic variants in the same HFTC-related <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</div></li><li class="half_rhythm"><div>The offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and an individual <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the same HFTC-related <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> have a 50% chance of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and 50% chance of being heterozygotes.</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>FGF23</i>, <i>GALNT3</i>, or <i>KL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. If there is a history of <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a>, the risk of being a carrier may be higher.</p></div><div id="hyper-ftc.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>FGF23</i>, <i>GALNT3</i>, or <i>KL</i> pathogenic variants in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member.</p></div><div id="hyper-ftc.Related_Genetic_Counseling_Iss"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#hyper-ftc.Evaluation_of_Relatives_at_Ris">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li><li class="half_rhythm"><div>Carrier testing for reproductive partners of known carriers is appropriate, particularly if <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a> is likely.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="hyper-ftc.Prenatal_Testing_and_Preimplan"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>FGF23, GALNT3,</i> or <i>KL</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="hyper-ftc.Resources"><h2 id="_hyper-ftc_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="https://ghr.nlm.nih.gov/condition/hyperphosphatemic-familial-tumoral-calcinosis" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hyperphosphatemic familial tumoral calcinosis</a></div></li></ul></div><div id="hyper-ftc.Molecular_Genetics"><h2 id="_hyper-ftc_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="hyper-ftc.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Hyperphosphatemic Familial Tumoral Calcinosis: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476672/table/hyper-ftc.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hyper-ftc.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_hyper-ftc.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_hyper-ftc.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_hyper-ftc.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_hyper-ftc.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_hyper-ftc.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_hyper-ftc.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_hyper-ftc.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/8074" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FGF23</i></a></td><td headers="hd_b_hyper-ftc.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=8074" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">12p13<wbr style="display:inline-block"></wbr>​.32</a></td><td headers="hd_b_hyper-ftc.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9GZV9" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fibroblast growth factor 23</a></td><td headers="hd_b_hyper-ftc.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/FGF23" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FGF23 database</a></td><td headers="hd_b_hyper-ftc.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FGF23" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FGF23</a></td><td headers="hd_b_hyper-ftc.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FGF23[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FGF23</a></td></tr><tr><td headers="hd_b_hyper-ftc.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2591" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>GALNT3</i></a></td><td headers="hd_b_hyper-ftc.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2591" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2q24<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_hyper-ftc.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q14435" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Polypeptide N-acetylgalactosaminyltransferase 3</a></td><td headers="hd_b_hyper-ftc.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/GALNT3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GALNT3 database</a></td><td headers="hd_b_hyper-ftc.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GALNT3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GALNT3</a></td><td headers="hd_b_hyper-ftc.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=GALNT3[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GALNT3</a></td></tr><tr><td headers="hd_b_hyper-ftc.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/9365" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>KL</i></a></td><td headers="hd_b_hyper-ftc.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=9365" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">13q13<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_hyper-ftc.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9UEF7" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Klotho</a></td><td headers="hd_b_hyper-ftc.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/KL" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KL @ LOVD</a></td><td headers="hd_b_hyper-ftc.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=KL" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KL</a></td><td headers="hd_b_hyper-ftc.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=KL[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KL</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="hyper-ftc.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="hyper-ftc.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Hyperphosphatemic Familial Tumoral Calcinosis (<a href="/omim/211900,601756,604824,605380" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476672/table/hyper-ftc.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hyper-ftc.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/211900" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">211900</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL, 1; HFTC1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601756" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601756</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 3; GALNT3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/604824" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">604824</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">KLOTHO; KL</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/605380" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">605380</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FIBROBLAST GROWTH FACTOR 23; FGF23</td></tr></tbody></table></div></div><p><b><i>FGF23</i></b></p><p><b>Gene structure.</b>
<i>FGF23</i> comprises three coding exons, spanning 10 kb of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> sequence. See <a href="/books/n/gene/hftc/#hftc.molgen.TA">Table A</a>, <b>Gene</b> for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information.</p><p><b>Pathogenic variants.</b> Nine <i>FGF23</i> pathogenic variants have been identified: eight <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants and one large intragenic <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>. The <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> c.211A&#x0003e;G has been identified most frequently (i.e., in 3/11 probands).</p><div id="hyper-ftc.T.fgf23_pathogenic_variants_di" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p><i>FGF23</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476672/table/hyper-ftc.T.fgf23_pathogenic_variants_di/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hyper-ftc.T.fgf23_pathogenic_variants_di_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hyper-ftc.T.fgf23_pathogenic_variants_di_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_hyper-ftc.T.fgf23_pathogenic_variants_di_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_hyper-ftc.T.fgf23_pathogenic_variants_di_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_hyper-ftc.T.fgf23_pathogenic_variants_di_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.211A&#x0003e;G</td><td headers="hd_h_hyper-ftc.T.fgf23_pathogenic_variants_di_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser71Gly</td><td headers="hd_h_hyper-ftc.T.fgf23_pathogenic_variants_di_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_020638.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_020638<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_065689.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_065689<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_hyper-ftc.T.fgf23_pathogenic_variants_di_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(5.25-Mb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>)&#x000a0;<sup>1</sup></td><td headers="hd_h_hyper-ftc.T.fgf23_pathogenic_variants_di_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="hyper-ftc.TF.4.1"><p class="no_margin"><a class="bk_pop" href="#hyper-ftc.REF.shah.2014.2235">Shah et al [2014]</a></p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> FGF23 has 251 amino acids and is secreted as an intact biologically active protein and also as processed inactive N-terminal and C-terminal fragments.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The pathogenic variants in <i>FGF23</i> causing HFTC result in reduced secretion of intact FGF23 and increased secretion of the inactive N-terminal and C-terminal fragments. Most (not all) reported <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> <i>FGF23</i> pathogenic variants affect putative glycosylation sites, either eliminating a serine or threonine residue or creating a serine or threonine residue.</p><p><b><i>GALNT3</i></b></p><p><b>Gene structure.</b>
<i>GALNT3</i> transcript <a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_004482.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004482.3</a> comprises 11 exons, one of which is noncoding. See <a href="/books/n/gene/hftc/#hftc.molgen.TA">Table A</a>, <b>Gene</b> for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information.</p><p><b>Pathogenic variants.</b> Thirty-five <i>GALNT3</i> pathogenic variants have been identified, including <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a>, and frameshift variants as well as insertions and deletions. See <a href="/books/n/gene/hftc/#hftc.molgen.TA">Table A</a>, <b>Locus-Specific Databases</b> and <b>HGMD</b>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>GALNT3</i> encodes a 633-amino acid protein, which has a single membrane-spanning region. The protein performs O-glycosylation of serine and threonine residues on an array of glycoproteins including FGF23. When FGF23 is O-glycosylated by GALNT3, it is protected from cleavage by a pro-protein convertase and is secreted in the intact, biologically active form. When FGF23 is not O-glycosylated, it is readily cleaved by a pro-protein convertase into inactive N-terminal and C-terminal fragments.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in <i>GALNT3</i> result in a protein that is presumed to be unable to O-glycosylate FGF23. Therefore, the FGF23 protein is readily cleaved into biologically inactive N-terminal and C-terminal fragments, resulting in reduced circulating intact FGF23.</p><p><b><i>KL</i></b></p><p><b>Gene structure.</b>
<i>KL</i> comprises five exons and spans approximately 50 kb of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. See <a href="/books/n/gene/hftc/#hftc.molgen.TA">Table A</a>, <b>Gene</b> for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information.</p><p><b>Pathogenic variants.</b> One <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KL</i> has been identified to date: a <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> c.578A&#x0003e;G transition in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1 resulted in a p.His19Arg substitution in the first of two tandem putative glycosidase domains [<a class="bk_pop" href="#hyper-ftc.REF.ichikawa.2007c.2684">Ichikawa et al 2007c</a>].</p><div id="hyper-ftc.T.kl_pathogenic_variants_discu" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p><i>KL</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476672/table/hyper-ftc.T.kl_pathogenic_variants_discu/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hyper-ftc.T.kl_pathogenic_variants_discu_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hyper-ftc.T.kl_pathogenic_variants_discu_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_hyper-ftc.T.kl_pathogenic_variants_discu_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_hyper-ftc.T.kl_pathogenic_variants_discu_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_hyper-ftc.T.kl_pathogenic_variants_discu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.578A&#x0003e;G</td><td headers="hd_h_hyper-ftc.T.kl_pathogenic_variants_discu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His193Arg</td><td headers="hd_h_hyper-ftc.T.kl_pathogenic_variants_discu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_004795.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004795<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_004786.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_004786<wbr style="display:inline-block"></wbr>​.2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Klotho is a 1,012-amino-acid protein that binds to FGFR1(IIIc), and together they form the FGF23 receptor.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KL</i> is predicted to destabilize the tertiary fold of the glycosidase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, leading to decreased expression and secretion of the protein. Absence of Klotho results in FGF23 resistance, in which intact biologically active FGF23 is unable to bind to its receptor. This, in turn, results in increase in circulating intact FGF23 as well as its inactive fragments.</p></div><div id="hyper-ftc.References"><h2 id="_hyper-ftc_References_">References</h2><div id="hyper-ftc.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.annamunthodo.1960.951">Annamunthodo H. Calcinosis. <span><span class="ref-journal">Am J Surg. </span>1960;<span class="ref-vol">99</span>:951–5.</span> [<a href="/pubmed/13793741" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13793741</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.benetpag_s.2005.385">Benet-Pag&#x000e8;s A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. <span><span class="ref-journal">Hum Mol Genet. </span>2005;<span class="ref-vol">14</span>:385–90.</span> [<a href="/pubmed/15590700" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15590700</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.bergwitz.2009.4267">Bergwitz C, Banerjee S, Abu-Zahra H, Kaji H, Miyauchi A, Sugimoto T, J&#x000fc;ppner H. Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2009;<span class="ref-vol">94</span>:4267–74.</span> [<a href="/pmc/articles/PMC2775647/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2775647</span></a>] [<a href="/pubmed/19837926" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19837926</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.boskey.1983.258">Boskey AL, Vigorita VJ, Sencer O, Stuchin SA, Lane JM. Chemical, microscopic, and ultrastructural characterization of the mineral deposits in tumoral calcinosis. <span><span class="ref-journal">Clin Orthop Relat Res. </span>1983;(178):258–69.</span> [<a href="/pubmed/6883859" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6883859</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.burkes.1991.222">Burkes EJ Jr, Lyles KW, Dolan EA, Giammara B, Hanker J. Dental lesions in tumoral calcinosis. <span><span class="ref-journal">J Oral Pathol Med. </span>1991;<span class="ref-vol">20</span>:222–7.</span> [<a href="/pubmed/2066872" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2066872</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.campagnoli.2006b.440">Campagnoli MF, Pucci A, Garelli E, Carando A, Defilippi C, Lala R, Ingrosso G, Dianzani I, Forni M, Ramenghi U. Familial tumoral calcinosis and testicular microlithiasis associated with a new mutation of GALNT3 in a white family. <span><span class="ref-journal">J Clin Pathol. </span>2006b;<span class="ref-vol">59</span>:440–2.</span> [<a href="/pmc/articles/PMC1860360/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1860360</span></a>] [<a href="/pubmed/16567474" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16567474</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.campagnoli.2006a.188">Campagnoli M, Rosipal S, Debreov&#x000e1; M, Rosipal R, Sala A, Romano A, Lab&#x000f2; S, Galliano M, Minchiotti L. Analbuminemia in a Slovak Romany (gypsy) family: case report and mutational analysis. <span><span class="ref-journal">Clin Chim Acta. </span>2006a;<span class="ref-vol">365</span>:188–93.</span> [<a href="/pubmed/16183048" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16183048</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.candrina.1989.55">Candrina R, Cerudelli B, Braga V, Salvi A. Effects of the acute subcutaneous administration of synthetic salmon calcitonin in tumoral calcinosis. <span><span class="ref-journal">J Endocrinol Invest. </span>1989;<span class="ref-vol">12</span>:55–7.</span> [<a href="/pubmed/2745932" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2745932</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.carmichael.2009.664">Carmichael KD, Bynum JA, Evans EB. Familial tumoral calcinosis: a forty-year follow-up on one family. <span><span class="ref-journal">J Bone Joint Surg Am. </span>2009;<span class="ref-vol">91</span>:664–71.</span> [<a href="/pubmed/19255228" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19255228</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.chefetz.2005.261">Chefetz I, Heller R, Galli-Tsinopoulou A, Richard G, Wollnik B, Indelman M, Koerber F, Topaz O, Bergman R, Sprecher E, Schoenau E. A novel homozygous missense mutation in FGF23 causes familial tumoral calcinosis associated with disseminated visceral calcification. <span><span class="ref-journal">Hum Genet. </span>2005;<span class="ref-vol">118</span>:261–6.</span> [<a href="/pubmed/16151858" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16151858</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.clarke.1984.643">Clarke E, Swischuk LE, Hayden CK Jr. Tumoral calcinosis, diaphysitis, and hyperphosphatemia. <span><span class="ref-journal">Radiology. </span>1984;<span class="ref-vol">151</span>:643–6.</span> [<a href="/pubmed/6718723" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6718723</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.demellawy.2015.170">Demellawy DE, Chang N, de Nanassy J, Nasr A. GALNT3 gene mutation-associated chronic recurrent multifocal osteomyelitis and familial hyperphosphatemic familial tumoral calcinosis. <span><span class="ref-journal">Scand J Rheumatol. </span>2015;<span class="ref-vol">44</span>:170–2.</span> [<a href="/pubmed/25351881" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25351881</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.dumitrescu.2009.1273">Dumitrescu CE, Kelly MH, Khosravi A, Hart TC, Brahim J, White KE, Farrow EG, Nathan MH, Murphey MD, Collins MT. A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features. <span><span class="ref-journal">Osteoporos Int. </span>2009;<span class="ref-vol">20</span>:1273–8.</span> [<a href="/pmc/articles/PMC2692468/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2692468</span></a>] [<a href="/pubmed/18982401" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18982401</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.favia.2014.569">Favia G, Lacaita MG, Limongelli L, Tempesta A, Laforgia N, Cazzolla AP, Maiorano E. Hyperphosphatemic familial tumoral calcinosis: odontostomatologic management and pathological features. <span><span class="ref-journal">Am J Case Rep. </span>2014;<span class="ref-vol">15</span>:569–75.</span> [<a href="/pmc/articles/PMC4278695/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4278695</span></a>] [<a href="/pubmed/25537063" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25537063</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.finer.2014.1545">Finer G, Price HE, Shore RM, White KE, Langman CB. Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms. <span><span class="ref-journal">Am J Med Genet A. </span>2014;<span class="ref-vol">164A</span>:1545–9.</span> [<a href="/pubmed/24668887" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24668887</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.foster.2014.7s">Foster BL, Ramnitz MS, Gafni RI, Burke AB, Boyce AM, Lee JS, Wright JT, Akintoye SO, Somerman MJ, Collins MT. Rare bone diseases and their dental, oral, and craniofacial manifestations. <span><span class="ref-journal">J Dent Res. </span>2014;<span class="ref-vol">93</span>:7S–19S.</span> [<a href="/pmc/articles/PMC4107543/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4107543</span></a>] [<a href="/pubmed/24700690" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24700690</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.frishberg.2005.33">Frishberg Y, Topaz O, Bergman R, Behar D, Fisher D, Gordon D, Richard G, Sprecher E. Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders. <span><span class="ref-journal">J Mol Med (Berl). </span>2005;<span class="ref-vol">83</span>:33–8.</span> [<a href="/pubmed/15599692" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15599692</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.garringer.2006.4037">Garringer HJ, Fisher C, Larsson TE, Davis SI, Koller DL, Cullen MJ, Draman MS, Conlon N, Jain A, Fedarko NS, Dasgupta B, White KE. The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2006;<span class="ref-vol">91</span>:4037–42.</span> [<a href="/pubmed/16868048" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16868048</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.garringer.2007.2390">Garringer HJ, Mortazavi SM, Esteghamat F, Malekpour M, Boztepe H, Tanakol R, Davis SI, White KE. Two novel GALNT3 mutations in familial tumoral calcinosis. <span><span class="ref-journal">Am J Med Genet A. </span>2007;<span class="ref-vol">143A</span>:2390–6.</span> [<a href="/pubmed/17853462" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17853462</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.gok.2009.131">Gok F, Chefetz I, Indelman M, Kocaoglu M, Sprecher E. Newly discovered mutations in the GALNT3 gene causing autosomal recessive hyperostosis-hyperphosphatemia syndrome. <span><span class="ref-journal">Acta Orthop. </span>2009;<span class="ref-vol">80</span>:131–4.</span> [<a href="/pmc/articles/PMC2823226/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2823226</span></a>] [<a href="/pubmed/19297793" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19297793</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.ichikawa.2010.896">Ichikawa S, Baujat G, Seyahi A, Garoufali AG, Imel EA, Padgett LR, Austin AM, Sorenson AH, Pejin Z, Topouchian V, Quartier P, Cormier-Daire V, Dechaux M, Malandrinou FCh, Singhellakis PN, Le Merrer M, Econs MJ. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. <span><span class="ref-journal">Am J Med Genet A. </span>2010;<span class="ref-vol">152A</span>:896–903.</span> [<a href="/pmc/articles/PMC3392654/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3392654</span></a>] [<a href="/pubmed/20358599" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20358599</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.ichikawa.2007a.1943">Ichikawa S, Guigonis V, Imel EA, Courouble M, Heissat S, Henley JD, Sorenson AH, Petit B, Lienhardt A, Econs MJ. Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2007a;<span class="ref-vol">92</span>:1943–7.</span> [<a href="/pubmed/17311862" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17311862</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.ichikawa.2007b.318">Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, Goetz R, Mohammadi M, White KE, Econs MJ. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. <span><span class="ref-journal">J Musculoskelet Neuronal Interact. </span>2007b;<span class="ref-vol">7</span>:318–9.</span> [<a href="/pubmed/18094491" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18094491</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.ichikawa.2007c.2684">Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, Goetz R, Mohammadi M, White KE, Econs MJ. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. <span><span class="ref-journal">J Clin Invest. </span>2007c;<span class="ref-vol">117</span>:2684–91.</span> [<a href="/pmc/articles/PMC1940239/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1940239</span></a>] [<a href="/pubmed/17710231" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17710231</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.ichikawa.2006.4472">Ichikawa S, Imel EA, Sorenson AH, Severe R, Knudson P, Harris GJ, Shaker JL, Econs MJ. Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2006;<span class="ref-vol">91</span>:4472–5.</span> [<a href="/pubmed/16940445" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16940445</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.ichikawa.2005.2420">Ichikawa S, Lyles KW, Econs MJ. A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2005;<span class="ref-vol">90</span>:2420–3.</span> [<a href="/pubmed/15687324" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15687324</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.joseph.2010.63">Joseph L, Hing SN, Presneau N, O'Donnell P, Diss T, Idowu BD, Joseph S, Flanagan AM, Delaney D. Familial tumoral calcinosis and hyperostosis-hyperphosphataemia syndrome are different manifestations of the same disease: novel missense mutations in GALNT3. <span><span class="ref-journal">Skeletal Radiol. </span>2010;<span class="ref-vol">39</span>:63–8.</span> [<a href="/pubmed/19830424" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19830424</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.jost.2016.2810">Jost J, Bahans C, Courbebaisse M, Tran TA, Linglart A, Benistan K, Lienhardt A, Mutar H, Pfender E, Ratsimbazafy V, Guigonis V. Topical sodium thiosulfate: a treatment for calcifications in hyperphosphatemic familial tumoral calcinosis? <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2016;<span class="ref-vol">101</span>:2810–5.</span> [<a href="/pubmed/27163355" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27163355</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.keskar.2015.1079">Keskar VS, Imel EA, Kulkarni M, Mane S, Jamale TE, Econs MJ, Hase NK. The case: ectopic calcifications in a child. <span><span class="ref-journal">Kidney Int. </span>2015;<span class="ref-vol">87</span>:1079–81.</span> [<a href="/pmc/articles/PMC4431583/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4431583</span></a>] [<a href="/pubmed/25951075" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25951075</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.krstevska.2012.416">Krstevska A, Gale S, Blair F. Tumoral calcinosis: a dental literature review and case report. <span><span class="ref-journal">Dent Update. </span>2012;<span class="ref-vol">39</span>:416–8, 421.</span> [<a href="/pubmed/22928454" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22928454</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.laleye.2008.183">Laleye A, Alao MJ, Gbessi G, Adjagba M, Marche M, Coupry I, Redonnet-Vernhet I, Lepreux S, Ayivi B, Darboux RB, Lacombe D, Arveiler B. Tumoral calcinosis due to GALNT3 C.516-2A &#x0003e;T mutation in a black African family. <span><span class="ref-journal">Genet Couns. </span>2008;<span class="ref-vol">19</span>:183–92.</span> [<a href="/pubmed/18618993" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18618993</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.lammoglia.2009.178">Lammoglia JJ, Mericq V. Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer. <span><span class="ref-journal">Horm Res. </span>2009;<span class="ref-vol">71</span>:178–84.</span> [<a href="/pubmed/19188744" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19188744</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.langman.2005">Langman CB, Salusky IB. K/DOQI Clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease - foreword. Am J Kidney Dis. Available <a href="https://www.kidney.org/sites/default/files/docs/bone_children_nkfguideline.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2005. Accessed 1-29-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.li_voon_chong.1999.262">Li Voon Chong SW, Ah Kion S, Cullen MJ. A report of familial hyperphosphataemia in an Irish family. <span><span class="ref-journal">Ir J Med Sci. </span>1999;<span class="ref-vol">168</span>:262–4.</span> [<a href="/pubmed/10624367" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10624367</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.lyles.1985.1093">Lyles KW, Burkes EJ, Ellis GJ, Lucas KJ, Dolan EA, Drezner MK. Genetic transmission of tumoral calcinosis: autosomal dominant with variable clinical expressivity. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>1985;<span class="ref-vol">60</span>:1093–6.</span> [<a href="/pubmed/3998061" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3998061</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.martinez.1990.215">Martinez S, Vogler JB 3rd, Harrelson JM, Lyles KW. Imaging of tumoral calcinosis: new observations. <span><span class="ref-journal">Radiology. </span>1990;<span class="ref-vol">174</span>:215–22.</span> [<a href="/pubmed/2294551" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2294551</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.masi.2015.438">Masi L, Beltrami G, Ottanelli S, Franceschelli F, Gozzini A, Zonefrati R, Galli G, Ciuffi S, Mavilia C, Giusti F, Marcucci G, Cioppi F, Colli E, Fossi C, Franchi A, Casentini C, Capanna R, Brandi ML. Human preosteoblastic cell culture from a patient with severe tumoral calcinosis-hyperphosphatemia due to a new GALNT3 gene mutation: study of in vitro mineralization. <span><span class="ref-journal">Calcif Tissue Int. </span>2015;<span class="ref-vol">96</span>:438–52.</span> [<a href="/pubmed/25899975" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25899975</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.masi.2009.1190">Masi L, Gozzini A, Franchi A, Campanacci D, Amedei A, Falchetti A, Franceschelli F, Marcucci G, Tanini A, Capanna R, Brandi ML. A novel recessive mutation of fibroblast growth factor-23 in tumoral calcinosis. <span><span class="ref-journal">J Bone Joint Surg Am. </span>2009;<span class="ref-vol">91</span>:1190–8.</span> [<a href="/pubmed/19411468" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19411468</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.mcgrath.2010.bcr0520103044">McGrath E, Harney F, Kinsella F. An ocular presentation of familial tumoral calcinosis. <span><span class="ref-journal">BMJ Case Rep. </span>2010;<span class="ref-vol">2010</span>:bcr0520103044.</span> pii. [<a href="/pmc/articles/PMC3029978/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3029978</span></a>] [<a href="/pubmed/22778290" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22778290</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.mcphaul.1961.488">McPhaul JJ Jr, Engel FL. Heterotopic calcification, hyperphosphatemia and angioid streaks of the retina. <span><span class="ref-journal">Am J Med. </span>1961;<span class="ref-vol">31</span>:488–92.</span> [<a href="/pubmed/13774168" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13774168</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.olauson.2008.929">Olauson H, Krajisnik T, Larsson C, Lindberg B, Larsson TE. A novel missense mutation in GALNT3 causing hyperostosis-hyperphosphataemia syndrome. <span><span class="ref-journal">Eur J Endocrinol. </span>2008;<span class="ref-vol">158</span>:929–34.</span> [<a href="/pubmed/18322299" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18322299</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.rafaelsen.2014.98">Rafaelsen S, Johansson S, R&#x000e6;der H, Bjerknes R. Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature. <span><span class="ref-journal">BMC Genet. </span>2014;<span class="ref-vol">15</span>:98.</span> [<a href="/pmc/articles/PMC4181413/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4181413</span></a>] [<a href="/pubmed/25249269" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25249269</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.ramnitz.2016.1845">Ramnitz MS, Gourh P, Goldbach-Mansky R, Wodajo F, Ichikawa S, Econs MJ, White KE, Molinolo A, Chen MY, Heller T, Del Rivero J, Seo-Mayer P, Arabshahi B, Jackson MB, Hatab S, McCarthy E, Guthrie LC, Brillante BA, Gafni RI, Collins MT. Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome. <span><span class="ref-journal">J Bone Miner Res. </span>2016;<span class="ref-vol">31</span>:1845–54.</span> [<a href="/pmc/articles/PMC5071128/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5071128</span></a>] [<a href="/pubmed/27164190" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27164190</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.shah.2014.2235">Shah A, Miller CJ, Nast CC, Adams MD, Truitt B, Tayek JA, Tong L, Mehtani P, Monteon F, Sedor JR, Clinkenbeard EL, White K, Mehrotra R, LaPage J, Dickson P, Adler SG, Iyengar SK. Severe vascular calcification and tumoral calcinosis in a family with hyperphosphatemia: a fibroblast growth factor 23 mutation identified by exome sequencing. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2014;<span class="ref-vol">29</span>:2235–43.</span> [<a href="/pmc/articles/PMC4240183/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4240183</span></a>] [<a href="/pubmed/25378588" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25378588</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.slavin.1993.788">Slavin RE, Wen J, Kumar D, Evans EB. Familial tumoral calcinosis. A clinical, histopathologic, and ultrastructural study with an analysis of its calcifying process and pathogenesis. <span><span class="ref-journal">Am J Surg Pathol. </span>1993;<span class="ref-vol">17</span>:788–802.</span> [<a href="/pubmed/8338191" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8338191</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.sprecher.2010.652">Sprecher E. Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification. <span><span class="ref-journal">J Invest Dermatol. </span>2010;<span class="ref-vol">130</span>:652–60.</span> [<a href="/pmc/articles/PMC3169303/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3169303</span></a>] [<a href="/pubmed/19865099" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19865099</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.steinherz.1985.816">Steinherz R, Chesney RW, Eisenstein B, Metzker A, DeLuca HF, Phelps M. Elevated serum calcitriol concentrations do not fall in response to hyperphosphatemia in familial tumoral calcinosis. <span><span class="ref-journal">Am J Dis Child. </span>1985;<span class="ref-vol">139</span>:816–9.</span> [<a href="/pubmed/3839626" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3839626</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.vieira.2015.e235">Vieira AR, Lee M, Vairo F, Loguercio Leite JC, Munerato MC, Visioli F, D'&#x000c1;vila SR, Wang SK, Choi M, Simmer JP, Hu JC. Root anomalies and dentin dysplasia in autosomal recessive hyperphosphatemic familial tumoral calcinosis (HFTC). <span><span class="ref-journal">Oral Surg Oral Med Oral Pathol Oral Radiol. </span>2015;<span class="ref-vol">120</span>:e235–9.</span> [<a href="/pmc/articles/PMC4640955/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4640955</span></a>] [<a href="/pubmed/26337219" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26337219</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.yamaguchi.1995.247s">Yamaguchi T, Sugimoto T, Imai Y, Fukase M, Fujita T, Chihara K. Successful treatment of hyperphosphatemic tumoral calcinosis with long-term acetazolamide. <span><span class="ref-journal">Bone. </span>1995;<span class="ref-vol">16</span>:247S–250S.</span> [<a href="/pubmed/7626311" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7626311</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyper-ftc.REF.yancovitch.2011.621">Yancovitch A, Hershkovitz D, Indelman M, Galloway P, Whiteford M, Sprecher E, K&#x00131;l&#x00131;&#x000e7; E. Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis. <span><span class="ref-journal">J Bone Miner Metab. </span>2011;<span class="ref-vol">29</span>:621–5.</span> [<a href="/pubmed/21347749" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21347749</span></a>]</div></li></ul></div></div><div id="hyper-ftc.Chapter_Notes"><h2 id="_hyper-ftc_Chapter_Notes_">Chapter Notes</h2><div id="hyper-ftc.Author_Notes"><h3>Author Notes</h3><p>Dr Collins&#x02019; <a href="https://www.nidcr.nih.gov/research/NIDCRLaboratories/CranioSkeletal/MichaelCollins.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">web page</a></p><p>Our research focuses on bone biology and mineral metabolism, which are studied through clinical and translational studies. Specific areas of interest include the role of PTH, G-proteins, and cAMP in bone cell biology, and FGF23 in mineral metabolism. The primary approach is the study and treatment of patients with rare disorders of bone and mineral metabolism as models through which to understand human bone and mineral biology and physiology. Current models of focus include fibrous dysplasia of bone, hypoparathyroidism, and disorders of FGF23 excess such as tumor-induced osteomalacia and <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> hypophosphatemic rickets and deficiency such as hyperphosphatemic <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> tumoral calcinosis.</p></div><div id="hyper-ftc.Acknowledgments"><h3>Acknowledgments</h3><p>This research was supported by the Intramural Research Program of the NIH, NIDCR.</p></div><div id="hyper-ftc.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>1 February 2018 (bp) Review posted live</div></li><li class="half_rhythm"><div>14 November 2016 (msr) Original submission</div></li></ul><p>Note: Pursuant to 17 USC Section 105 of the United States Copyright Act, the <i>GeneReview</i> "Hyperphosphatemic Familial Tumoral Calcinosis" is in the public <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> in the United States of America.</p></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK476672</span><span class="label">PMID: <a href="/pubmed/29389098" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">29389098</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/hhhs/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/hyper-card/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK476672&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK476672/?report=reader">PubReader</a></li><li><a href="/books/NBK476672/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK476672" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK476672" style="display:none" title="Cite this Page"><div class="bk_tt">Ramnitz MS, Gafni RI, Collins MT. Hyperphosphatemic Familial Tumoral Calcinosis. 2018 Feb 1. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK476672/pdf/Bookshelf_NBK476672.pdf">PDF version of this page</a> (1.5M)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#hyper-ftc.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#hyper-ftc.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#hyper-ftc.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#hyper-ftc.Genetically_Related_Allelic_Di" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#hyper-ftc.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#hyper-ftc.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#hyper-ftc.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#hyper-ftc.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#hyper-ftc.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#hyper-ftc.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#hyper-ftc.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2591[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">GALNT3</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=4497292" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4497292" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4497292" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=4497292" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25249269" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.</a><span class="source">[BMC Genet. 2014]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Rafaelsen S, Johansson S, Ræder H, Bjerknes R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">BMC Genet. 2014 Sep 24; 15:98. Epub 2014 Sep 24.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24668887" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms.</a><span class="source">[Am J Med Genet A. 2014]</span><div class="brieflinkpop offscreen_noflow">Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Finer G, Price HE, Shore RM, White KE, Langman CB. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Med Genet A. 2014 Jun; 164A(6):1545-9. Epub 2014 Mar 25.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29594503" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Hyperphosphatemic tumoral calcinosis caused by FGF23 compound heterozygous mutations: what are the therapeutic options for a better control of phosphatemia?</a><span class="source">[Pediatr Nephrol. 2018]</span><div class="brieflinkpop offscreen_noflow">Hyperphosphatemic tumoral calcinosis caused by FGF23 compound heterozygous mutations: what are the therapeutic options for a better control of phosphatemia?<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Claramunt-Taberner D, Bertholet-Thomas A, Carlier MC, Dijoud F, Chotel F, Silve C, Bacchetta J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Pediatr Nephrol. 2018 Jul; 33(7):1263-1267. Epub 2018 Mar 28.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27164190" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.</a><span class="source">[J Bone Miner Res. 2016]</span><div class="brieflinkpop offscreen_noflow">Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ramnitz MS, Gourh P, Goldbach-Mansky R, Wodajo F, Ichikawa S, Econs MJ, White KE, Molinolo A, Chen MY, Heller T, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Bone Miner Res. 2016 Oct; 31(10):1845-1854. Epub 2016 Sep 20.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25656441" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.</a><span class="source">[Curr Osteoporos Rep. 2015]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Folsom LJ, Imel EA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Curr Osteoporos Rep. 2015 Apr; 13(2):78-87. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=29389098" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=29389098" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5dfc87aa39a66ee2bab5d172">Hyperphosphatemic Familial Tumoral Calcinosis - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Hyperphosphatemic Familial Tumoral Calcinosis - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-20T03:34:51-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE88A54BDFC759110000000008120408&amp;ncbi_session=CE88A54BDFC87AA1_2066SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK476672%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK476672&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK476672/&amp;ncbi_pagename=Hyperphosphatemic Familial Tumoral Calcinosis - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88A54BDFC87AA1_2066SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>